Allergy Choices Testimonial

Treatment is simple, with just one drop under the tongue three times daily and a quarterly visit with the doctor. — Stephanie, mother of patient in TX

Sublingual Immunotherapy Research Bibliography

v.10/16

The current understanding of clinical efficacy, safety, mechanisms and indications for the use of sublingual-swallow immunotherapy (SLIT) in the treatment of allergies is embodied in the studies, papers and publications referenced in this document. Over 825 citations are contained in this bibliography, including hundreds of peer-reviewed studies published since 1995.

Internationally, SLIT is used widely (50% in some European countries), with full regulatory and government backing. U.S. allergy leaders are writing in support of SLIT. (See section 1) The World Health Organization indicated its use in its 1998 position paper. In 2007, for the second time (originally in 2001), an international workgroup, including U.S. allergists, published the ARIA (Allergy Rhinitis and its Impact on Asthma) guidelines indicating SLIT as a viable treatment approach. The ARIA paper indicates that not only is there more modern research on SLIT compared to SCIT, but it is also of higher quality in terms of the WHO guidelines for research studies. A Cochrane Review, the most trusted independent, evidence based, meta-analysis organization in the world, released their analysis in 2003 and determined SLIT both safe and effective (see section 1).

Two additional pivotal studies to note are the “10 year study…” showing the long lasting effect of SLIT (see section 1), and the 2004 head-to-head study of SLIT to injection in a double-blind, double-dummy approach (see section 2). Few studies have shown that SLIT was not effective, and those results are equivocal or dated.

Additional research efforts are underway in the U.S. and internationally; this document is updated periodically to include recent publications. Last updated 10/01/16.

Scientific research and related publications
The following pages are a comprehensive bibliography of studies divided into seven categories, with citations presented in chronological order:

  1. Recent Major Texts, Guidelines, Reviews, Papers and Editorials includes 220 major position papers
  2. Studies/Abstracts includes over 200 studies
  3. Comparison Studies of Sublingual and Subcutaneous Antigen Administration
  4. Mechanisms of Sublingual Immunotherapy; current understanding of mucosal immunity
  5. Safety, Quality-of-Life and Adherence Related Studies; growing body of evidence
  6. Other Indications for Treatment; other sensitizations where SLIT has worked
  7. Allergic Trends and Supporting Data

The scrutiny of SLIT has been intense, particularly in the past five to 10 years. The volume of research and its consistency in showing safety and efficacy is evidence of the value of SLIT to patients. We thank you for your interest in this topic and invite you to provide us feedback and let us know if you would like to receive updates of new research and publications as they are added.

1. Recent Major Texts, Guidelines, Reviews, Papers and Editorials

  1. Demoly P, Passalacqua G, Pfaar O, et al. Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. Allergy, Asthma & Clinical Immunology. 2016 Jul 29;12:34. doi: 10.1186/s13223-016-0140-2.
  2. Ferrando M, Bagnasco D, Passalacqua G, et al. MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy. 2016 Nov;16(11):1435-1441.
  3. Ponce M, Diesner SC, Szépfalusi Z, et al. Markers of tolerance development to food allergens. Allergy. 2016 Oct;71(10):1393-404. doi: 10.1111/all.12953.
  4. Miceli Sopo S, Battista A, Greco M, et al. Grass pollen sublingual immunotherapy and pediatric allergic rhinitis: A patient-oriented decision. Allergologia et Immunopathologia. 2016 Jul-Aug;44(4):382-6. doi: 10.1016/j.aller.2015.05.004.
  5. Larenas-Linnemann D, Baxi S, Phipatanakul W, et al. Clinical Evaluation and Management of Patients with Suspected Fungus Sensitivity. Journal of Allergy and Clinical Immunology. 2016 May-Jun;4(3):405-14. doi: 10.1016/j.jaip.2015.10.015.
  6. Benedé S, Blázquez AB, Chiang D, et al. The rise of food allergy: Environmental factors and emerging treatments. EBioMedicine. 2016 May;7:27-34. doi: 10.1016/j.ebiom.2016.04.012.
  7. Hanci D, Şahin E, Muluk NB, et al. Immunotherapy in all aspects. European Archives of Oto-Rhino-Laryngology. 2016 Jun;273(6):1347-55. doi: 10.1007/s00405-015-3553-5.
  8. Moingeon P, Cox L. Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America. Expert Review of Clinical Immunology. 2016 Jun;12(6):617-23. doi: 10.1586/1744666X.2016.1147349.
  9. Pesek RD, Jones SM. Current and Emerging Therapies for IgE-Mediated Food Allergy. Current Allergy and Asthma Reports. 2016 Apr;16(4):28. doi: 10.1007/s11882-016-0610-0.
  10. Mims JW. Current concepts: diagnosis and management of food allergy in children. Current Opinion in Otolaryngology & Head and Neck Surgery. 2016 Jun;24(3):250-5. doi: 10.1097/MOO.0000000000000261.
  11. Commins SP, Kim EH, Orgel K, et al. Peanut Allergy: New Developments and Clinical Implications. Current Allergy and Asthma Reports. 2016 May;16(5):35. doi: 10.1007/s11882-016-0613-x.
  12. Wood RA. Food allergen immunotherapy: Current status and prospects for the future. Journal of Allergy and Clinical Immunology. 2016 Apr;137(4):973-82. doi: 10.1016/j.jaci.2016.01.001.
  13. Nowak-Węgrzyn A. Using Food and Nutritional Strategies to Induce Tolerance in Food-Allergic Children. Nestlé Nutrition Workshop Series. 2016;85:35-53. doi: 10.1159/000439484.
  14. Slavyanakaya TA, Derkach VV, Sepiashvili RI. Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. World Allergy Organization Journal. 2016 Apr 18;9:15. doi: 10.1186/s40413-016-0106-3.
  15. Larsson O, Hellkvist L, Peterson-Westin U, et al. Novel strategies for the treatment of grass pollen-induced allergic rhinitis. Expert Opinion on Biological Therapy. 2016 Sep;16(9):1143-50. doi: 10.1080/14712598.2016.1190829
  16. Canonica GW, Virchow JC, Zieglmayer P, et al. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. Expert Review of Clinical Immunology. 2016 Aug;12(8):805-15. doi: 10.1080/1744666X.2016.1200467.
  17. Trendelenburg V, Blümchen K. Allergen-specific immunotherapy for food allergies in childhood. Current options and future perspectives. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Jul;59(7):855-64. doi: 10.1007/s00103-016-2372-1.
  18. Saporta D. Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice. BioMed Research International. 2016;2016:9323804. doi: 10.1155/2016/9323804.
  19. Creticos PS, Bernstein DI, Casale TB, et al. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. Journal of Allergy and Clinical Immunology. 2016 Jun 24. pii: S2213-2198(16)30153-2. doi: 10.1016/j.jaip.2016.05.014. [Epub ahead of print]
  20. Đurić-Filipović I, Caminati M, Kostić G, et al. Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. World Journal of Pediatrics. 2016 Aug;12(3):283-90. doi: 10.1007/s12519-016-0022-1.
  21. Cardona V, Luengo, Labrador-Horrillo M. Immunotherapy in allergic rhinitis and lower airway outcomes. 2016 Jul 20. doi: 10.1111/all.12989. [Epub ahead of print]
  22. Pepper AN, Calderón MA, Casale TB. Sublingual Immunotherapy for the Polyallergic Patient. Journal of Allergy and Clinical Immunology. 2016 Jul 21. pii: S2213-2198(16)30262-8. doi: 10.1016/j.jaip.2016.06.019. [Epub ahead of print]
  23. Lawrence MG, Steinke JW, Borish L. Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy. Annals of Allergy, Asthma & Immunology. 2016 Aug;117(2):138-42. doi: 10.1016/j.anai.2016.06.027.
  24. Yukselen A. Allergen-specific immunotherapy in pediatric allergic asthma. Asia Pacific Allergy. 2016 Jul;6(3):139-48. doi: 10.5415/apallergy.2016.6.3.139.
  25. Passalacqua G, Nowak-Węgrzyn A, Canonica GW. Local Side Effects of Sublingual and Oral Immunotherapy. Journal of Allergy and Clinical Immunology. 2016 Aug 12. pii: S2213-2198(16)30263-X. doi: 10.1016/j.jaip.2016.06.020. [Epub ahead of print]
  26. Demoly P, Okamoto Y, Yang WH, et al. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Expert Review of Clinical Immunology. 2016 Nov;12(11):1141-1151. Epub 2016 Sep 29.
  27. Kobernick AK, Burks AW. Active treatment for food allergy. Allergology International. 2016 Oct;65(4):388-395. doi: 10.1016/j.alit.2016.08.002.
  28. Oktemer T, Altıntoprak N, Muluk NB, et al. Clinical efficacy of immunotherapy in allergic rhinitis. The American Journal of Rhinology & Allergy. 2016 Sep;30 suppl. 1(5):4-7.
  29. Anderson HM, Wood RA, Busse WW. Dust Mite-Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy. Journal of Allergy and Clinical Immunology. 2016 Sep 21. pii: S2213-2198(16)30315-4. doi: 10.1016/j.jaip.2016.07.013. [Epub ahead of print]
  30. Alterio T, Manti S, Colavita L. Sublingual immunotherapy in children: State of art. Journal of Biological Regulators & Homeostatic Agents. 2015 Apr-Jun;29 (2 Suppl 1):120-4. [Epub ahead of print]
  31. Cox LS, Didier A, Demoly P, et al. Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. Journal of Allergy and Clinical Immunology. 2016 Apr 12. doi: 10.1016/j.jaci.2016.01.039. [Epub ahead of print]
  32. Pesek RD, Jones SM. Current and emerging therapies for IgE-mediated food allergy. Current Allergy and Asthma Reports. 2016 Apr;16(4):28. doi: 10.1007/s11882-016-0610-0. [Epub ahead of print]
  33. Wood, RA. Food allergen immunotherapy: Current status and prospects for future. Journal of Allergy and Clinical Immunology. 2016 Apr;137(4):973-982. doi: 10.1016/j.jaci.2016.01.001. [Epub ahead of print]
  34. Wurtzen PA, Gupta S, Brand S, Andersen PS. Grass pollen immunotherapy: Where are we now. Immunotherapy. 2016 Apr;8(4):399-411. doi: 10.2217/imt.16.1. [Epub ahead of print]
  35. Mims JW. Current concepts: diagnosis and management of food allergy in children. Current Opinion in Otolaryngology & Head and Neck Surgery. 2016 Mar 15. doi: 10.1097/MOO.0000000000000261. [Epub ahead of print]
  36. Jutel M, Bartkowiak-Emeryk M, Breborowicz A, et al. Sublingual immunotherapy (SLIT) – indications, mechanism, and efficacy position paper prepared by the Section of Immunotherapy, Polish Society of Allergy. Annals of Agricultural and Environmental Medicine. 2016 Mar;23(1):44-53. doi: 10.5604/12321966.1196851. [Epub ahead of print]
  37. Nguyen NT, Raskopf E, Shah-Hosseini K, Zadoyan G, Mösges R. A review of allergoid immunotherapy: Is cat allergy a suitable target? Immunotherapy. 2016 Mar;8(3):331-349. doi: 10.2217/imt.15.121. Epub 2016 Feb 9.
  38. Tam H, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database of Systematic Reviews. 2016 Feb 12;2:CD008774. doi: 10.1002/14651858.CD008774.pub2. [Epub ahead of print]
  39. Poddighe D, Licari A, Caimmi S, et al. Sublingual immunotherapy for pediatric allergic rhinitis: The clinical evidence. World Journal of Clinical Pediatrics. 2016 Feb 8;5(1):47-56. doi: 10.5409/wjcp.v5.i1.47. eCollection 2016.
  40. Song TW. A practical view of immunotherapy for food allergy. Korean Journal of Pediatrics. 2016 Feb;59(2):47-53. doi: 10.3345/kjp.2016.59.2.47. Epub 2016 Feb 29.
  41. Larenas-Linnemann D, Baxi S, Phipatanakul W, Portnoy JM, Environmental Allergens Workgroup. Clinical evaluation and management of patients with suspected fungus sensitivity. Journal of Allergy and Clinical Immunology: In Practice. 2016 Jan 2. pii: S2213-2198(15)00625-X. doi: 10.1016/j.jaip.2015.10.015. [Epub ahead of print]
  42. Cox L. The role of allergen immunotherapy in the management of allergic rhinitis. American Journal of Rhinology & Allergy. 2016 Jan;30(1):48-53. doi: 10.2500/ajra.2016.30.4253. [Epub Jan 2016]
  43. Sur DK, Plesa ML. Treatment of allergic rhinitis. American Family Physician. 2015 Dec 1;92(11):985-992. [Epub ahead of print]
  44. Didier A, Campo P, Moreno F, Durand-Perdriel F, Marin A, Chartier A. Dose-dependent immunological responses after a 6-month course of sublingual house dust mite immunotherapy in patients with allergic rhinitis. International Archives of Allergy and Immunology. 2015;168(3):182-192. doi: 10.1159/000442467. Epub 2016 Jan 21.
  45. Passalacgua G, Canonica GW. Allergen immunotherapy: History and future developments. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):1-12. doi: 10.1016/j.iac.2015.08.001. Epub 2015 Oct 21.
  46. Canonica GW, Bagnasco D, Ferrantino G, Ferrando M, Passalacgua G. Update on immunotherapy for the treatment of asthma. Current Opinion in Pulmonary Medicine. 2016 Jan;22(1):18-24. doi: 10.1097/MCP.0000000000000227.
  47. Larenas-Linnemann, D. Allergen immunotherapy: an update on protocols of administration. Current Opinion in Allergy and Clinical Immunology. 2015 Dec;15(6):556-567. doi:10.1097/ACI.0000000000000220.
  48. Masuyama K, et al. Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. Auris Nasus Larynx. 2015 Nov 23. pii: S0385-8146(15)00225-4. doi: 10.1016/j.anl.2015.08.015. [Epub ahead of print]
  49. Incorvaia C, Mauro M, Ridolo E. Sublingual immunotherapy for allergic rhinitis: where are we now? Immunotherapy. 2015 Oct 28. doi:10.2217/imt.15.72. [Epub ahead of print]
  50. Arasi S, Passalacugua G, Caminiti L, Crisafulli G, Fiamingo C, Pajno GB. Efficacy and safety of sublingual immunotherapy in children. Expert Review of Clinical Immunology. 2015 Oct 17;1-8. doi: 10.1586/1744666X.2016.1102058. [Epub ahead of print]
  51. Mener DJ, Lin SY. Improvement and prevention of asthma with concomitant treatment of allergic rhinitis and allergen-specific therapy. International Forum of Allergy & Rhinology. 2015 Sep;5 Suppl 1:S45-50. doi: 10.1002/alr.21569. Epub 2015 Jun 13.
  52. Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. Drug Discovery Today. 2015 Sep 2. doi: 10.1016/j.drudis.2015.07.010. [Epub ahead of print]
  53. Leatherman BD, et al. Dosing of sublingual immunotherapy for allergic rhinitis: evidence-based review with recommendations. International Forum of Allergy & Rhinology. 2015 Sep;5(9):773-83. doi: 10.1002/alr.21561. Epub 2015 Jun 11.
  54. Pleskovic N, Bartholow A, Gentile DA, Skoner DP. The future of sublingual immunotherapy in the United States. Current Allergy and Asthma Reports. 2015 Aug; 15(8):44. doi: 10.1007/s11882-015-0545-x. Epub 2015 Jul 7.
  55. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis. JAMA Internal Medicine. 2015 Aug;175(8):1301-9. doi: 10.1001/jamainternmed.2015.2840.
  56. van der Valk JP, de Jong NW, Gerth van Wijk R. Review on immunotherapy in airway allergen sensitised patients. Netherlands Journal of Medicine. 2015 Jul;73(6):263-9. Retrieved December 4, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26228190
  57. McDonell AL, et al. Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis. Allergy, Asthma & Clinical Immunology. 2015 Jun 10;11(1):19. doi: 10.1186/s13223-015-0085-x. eCollection 2015.
  58. Cox L. Allergy immunotherapy in reducing healthcare cost. Current Opinion in Otolaryngology & Head and Neck Surgery. 2015 Jun;23(3):247-54. doi: 10.1097/MOO.0000000000000150.
  59. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. The New England Journal of Medicine. 2015 Jan 29;372(5):456-63. doi: 10.1056/NEJMcp1412282.
  60. Nelson, HS. Allergen immunotherapy: what’s new, what’s next? Expert Review of Clinical Immunology. 2015;11(9):959-61. doi: 10.1586/1744666X.2015.1062726. Epub 2015 Jul 1.
  61. Didier A1, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opinion on Drug Safety. 2015 May;14(5):777-88. doi: 10.1517/14740338.2015.1017468. Epub 2015 Mar 3.
  62. Scadding GK. Optimal management of allergic rhinitis. Archives of Disease in Childhood. 2015 Jun;100(6):576-582. doi: 10.1136/archdischild-2014-306300. Epub 2015 Apr 2.
  63. Nony E2, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy. 2015 Apr 2. doi: 10.1111/all.12622. [Epub ahead of print]
  64. Lee S1, Nolte H, Benninger MS. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. American Journal of Rhinology & Allergy. 2015 Mar-Apr;29(2):106-14. doi: 10.2500/ajra.2015.29.4148.
  65. El-Qutob D1, Reche P, Subiza JL, Fernandez-Caldas E. Peptide-based allergen specific immunotherapy for the treatment of allergic disorders. Recent Patents of Inflammation & Allergy Drug Discovery. 2015;9(1):16-22.
  66. Kim ST1. Outcome of sublingual immunotherapy in patients with allergic rhinitis sensitive to house dust mites. Allergy, Asthma & Immunology Research. 2015 Mar;7(2):99-100. doi: 10.4168/aair.2015.7.2.99. Epub 2014 Feb 23.
  67. Ihler F1, Canis M. Ragweed-induced allergic rhinoconjunctivitis: current and emerging treatment options. Journal of Asthma and Allergy. 2015 Feb 16;8:15-24. doi: 10.2147/JAA.S47789. eCollection 2015.
  68. Choi JS1, et al. Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. Annals of Dermatology. 2015 Feb;27(1):82-6. doi: 10.5021/ad.2015.27.1.82. Epub 2015 Feb 3.
  69. Seidman MD1, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngology Head and Neck Surgery. 2015 Feb;152(2):197-206. doi: 10.1177/0194599814562166.
  70. Hsiao KC, Smart J. Comment on ‘Anaphylaxis caused by in –season switchover of sublingual immunotherapy formulation. Pediatric Allergy and Immunology. 2015 Feb;26(1):92. doi: 10.1111/pai.12329.
  71. Gendelman SR1, Lang DM. Sublingual immunotherapy in the treatment of atopic dermatitis; a systematic review using the GRADE system. Current Allergy and Asthma Reports. 2015 Feb;15(2):498. doi: 10.1007/s11882-014-0498-5.
  72. Refaat M1, Ashour ZA, Farres MN, Eissa AM, Elsayed MM. Effect of tonsillectomy on the efficacy of house dust mite sublingual immunotherapy. Allergologia et Immunopathologia (Madrid). 2015 Jan-Feb;43(1):108-11. doi: 10.1016/j.aller.2013.09.007. Epub 2014 Jan 2.
  73. Nakonechna A1, Hills J, Moor J, Dore P, Abuzakouk M. Grazax sublingual immunotherapy in pre-co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy? Annals of Allergy, Asthma & Immunology. 2015 Jan;114(1):73-4. doi: 10.1016/j.anai.2014.10.013. Epub 2014 Nov 14.
  74. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? Current Opinion in Allergy and Clinical Immunology. 2014 Dec;14(6):542-8. doi: 10.1097/ACI.0000000000000104.
  75. Biagtan M1, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Current Allergy and Asthma Reports. 2014 Dec;14(12):482. doi: 10.1007/s11882-014-0482-0.
  76. Wang C1, Zhang L. Specific immunotherapy for allergic rhinitis in children. Current Opinion in Otolarynology & Head and Neck Surgery. 2014 Dec;22(6):487-94. doi: 10.1097/MOO.0000000000000101.
  77. Makatsori M1,Calderon MA. Sublingual allergen immunotherapy for respiratory allergies: what is new? Expert Review of Clinical Immunology. 2014 Dec;10(12):1641-7. doi: 10.1586/1744666X.2014.982536.
  78. Yoon, HI1. Respiratory review of 2015: asthma. Tuberculosis and Respiratory Diseases. 2014 Dec;77(6):237-42. doi: 10.4046/trd.2014.77.6.237. Epub 2014 Dec 31.
  79. Moingeon P1. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Review of Vaccines. 2014 Dec;13(12):1463-73. doi: 10.1586/14760584.2014.948861. Epub 2014 Sep 4.
  80. Bahceciler NN1, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mie-allergen immunotherapy: the new sublingual tablet S-524101 (actair). Expert Review of Vaccines. 2014 Dec;13(12):1427-38. doi: 10.1586/14760584.2014.972949. Epub 2014 Oct 27.
  81. Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. World Journal of Clinical Cases. 2014 Dec 16;2(12):859-65. doi: 10.12998/wjcc.v2.i12.859.
  82. Pleskovic N1, Bartholow A, Skoner DP. Sublingual Immuotherapy in children: the recent experiences. Current Opinion in Allergy and Clinical Immunology. 2014 Dec;14(6):582-90. doi: 10.1097/ACI.0000000000000112.
  83. Aboshady OA1, Elghanam KM1. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. Clinical & Experimental Otorhinolaryngology. 2014 Dec;7(4):241-9. doi: 10.3342/ceo.2014.7.4.241. Epub 2014 Nov 14
  84. Antico A1. Long-term adherence to sublingual therapy: literature review and suggestions for management strategies based on patients’ needs and preferences. Clinical and Experimental Allergy. 2014 Nov;44(11):1314-26. doi: 10.1111/cea.12362.
  85. Ishida W1, Fukuda K, Harada Y, Yagita H, Fukushima A. Oral immunotherapy for allergic conjunctivitis. Cornea. 2014 Nov;33 Suppl 11:S32-6. doi: 10.1097/ICO.0000000000000241.
  86. Nelson HS1. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Review of Clinical Immunology. 2014 Nov;10(11):1437-51. doi: 10.1586/1744666X.2014.963556.
  87. Calderon MA1, Bernstein DI, Blaiss M, Andersen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. Clinical and Experimental Allergy. 2014 Oct;44(10):1228-39. doi: 10.1111/cea.12331.
  88. Lin SY. Sublingual immunotherapy: current concepts for the U.S. practitioner. International Forum of Allergy & Rhinology. 2014 Sep;4 Suppl 2:S55-9. doi: 10.1002/alr.21388.
  89. Didier A1, Wahn, Horak F, Cox L. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen induced allergic rhinoconjunctivitis: 5 years of experience. Expert Review of Clinical Immunology. 2014 Oct;10(10):1309-24. doi: 10.1586/1744666X.2014.957677. Epub 2014 Sep 10.
  90. Ryan MW1, Marple BF, Leatherman B, Mims JW, Fornadley J, Veling M, Lin SY. Current practice trends in allergy: results of a United States survey of otolaryngologists, allergist-immunologists, and primary care physicians. International Forum of Allergy & Rhinology. 2014 Oct;4(10):789-95. doi: 10.1002/alr.21359. Epub 2014 Aug 5.
  91. Yalaoui T1, de Beaumont O. Comments on: “Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation”. Pediatric Allergy and Immunology. 2014 Oct 9. doi: 10.1111/pai.12290. [Epub ahead of print]
  92. Leatherman B1, et al. The Allergies, Immunotherapy and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. International Forum of Allergy & Rhinology. 2014 Oct;4(10):779-88. doi: 10.1002/alr.21349. Epub 2014 Aug 14.
  93. Pleskovic N1, Bartholow A, Skoner DP. Sublingual immunotherapy in children: the recent experiences. Current Opinion in Allergy and Clinical Immunology. 2014 Dec;14(6):582-90. doi: 10.1097/ACI.0000000000000112.
  94. Nelson HS. Update on house dust mite immunotherapy: are more studies needed? Current Opinion in Allergy and Clinical Immunology. 2014 Dec;14(6):542-8. doi: 10.1097/ACI.0000000000000104.
  95. Grundmann SA1, Mosers P, Brehler R. [Specific immunotherapy] [Article in German]. Hautärzte. 2014 Jul;65(7):633-45; quiz 646-7. doi: 10.1007/s00105-014-2817-0.
  96. Anolik R1, Schwarz AM, Sajjan S, Allen-Ramey F. Patient initiation and persistence with allergen immunotherapy. Annals of Allergy, Asthma & Immunology. 2014 Jul;113(1):101-7. doi: 10.1016/j.anai.2014.04.008. Epub 2014 May 9.
  97. Pfaar O1, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014 Jul;69(7):854-67. doi: 10.1111/all.12383. Epub 2014 Apr 25.
  98. Castillo J1, Dimov V. Investigational drugs for the treatment of allergic rhinitis. Expert Opinion on Investigational Drugs. 2014 Jun;23(6):823-36. doi: 10.1517/13543784.2014.907271. Epub 2014 Apr 8.
  99. Linkov G1, Toskala E. Sublingual immunotherapy: what we can learn from the European experience. Current Opinion in Otolaryngology & Head and Neck Surgery. 2014 Jun;22(3):208-10. doi: 10.1097/MOO.0000000000000042.
  100. Skoner DP1, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients’ experience with allergen immunotherapy. Allergy & Asthma Proceedings. 2014 May-Jun;35(3):219-26. doi: 10.2500/aap.2014.35.3752.
  101. Hafner D1, Godicke V, Narkus A. Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies. Clinical and Translational Allergy. 2014 May 22;4:18. doi: 10.1186/2045-7022-4-18. eCollection 2014.
  102. Riedmann EM. Human Vaccines & Immunotherapeutics: News. FDA approval for Stallergenes’ sublingual grass pollen allergy immunotherapy. Human Vaccines & Immunotherapeutics. 2014 May;10(5):1141-42. doi: 10.4161/hv.29344.
  103. Wu YY, Xie XM, Han D, Li SJ, Liu L, Li MX. [A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma]. [Article in Chinese]. Zhonghua Nei Ke Za Zhi. [Chinese Journal of Internal Medicine]. 2013 Oct;52(10):844-848.
  104. Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. Journal of Allergy and Clinical Immunology: In Practice. 2013 Jul-Aug;1(4):361-369.
  105. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, Barton P, Dretzke J. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technology Assessment. 2013 Jul;17(27):vi, xi-xiv, 1-322.
  106. Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE. Pediatric sublingual immunotherapy efficacy: evidence analysis 2009-2012. Annals of Allergy, Asthma & Immunology. 2013 Jun;110(6):402-415.
  107. Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. Journal of Asthma. 2014 Feb;51(1):20-33.
  108. Milani M, Allergen-specific immunotherapy for allergic rhinitis in the elderly: is it never too late? Immunotherapy. 2013 July;5(5):699-702.
  109. Canonica et al (Canonica GW, Cox L, Pawanker R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Claderón M, Durham SR, Gerth van Wijk R, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosario N, Ryan D, Rosenwasser L, Schmid-Grendelmeier R, Gianenrico S, Valvovirta E, Van Bever H, Vichyanond P, Wahn U, and Yusuf O). Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal. 2014;7:6:1-52
  110. Passalacqua G, Garelli V, Scilfo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy. 2013;5(3):257-64.
  111. Incorvaia C, Barbera S., Makri E, Mauro M. Allergic rhinitis: pathology of general interest. Recenti Progressi in Medicina. 2013;104(3):116-9.
  112. An update on the management of hay fever in adults. Drug and Therapeutics Bulletin. 2013;51(3):30-3.
  113. Potter P. Sublingual immunotherapy in southern Africa: Lessons learned. Journal of Allergy and Clinical Immunology. 2013. Epub ahead of print retrieved May 13, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23587331
  114. Klimek L, Pfaar O. A comparison of immunotherapy delivery methods for allergen immunotherapy. Expert Review of Clinical Immunology. 2013;9(5):465-75.
  115. Chiriac AM, Demoly P. Respiratory allergies. Presse Medicale. 2013;42(4 Pt 1):395-404.
  116. Kim JM, Lin SY, Suarez-Cuervo C., Chelladurai Y, Ramanathan M, Segal JB, Erekosima N. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: A systematic review. Pediatrics. 2013. Epub ahead of print retrieved May 13, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23650298
  117. Bae, JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology. 2013. Epub ahead of print retrieved May 13, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23647790
  118. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, Ward D, Segal JB. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. Journal of American Medical Association. 2013;309(12):1278-88.
  119. Dretzke J., Meadows, A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison. Journal of Allergy and Clinical Immunology. 2013;131(5):1361-6.
  120. Vitaliti G, Pavone P, Guglielmo F, Falsaperla R. Sublingual immunotherapy in preschool children: an update. Expert Review of Clinical Immunology. 2013;9(4):385-90.
  121. Ramsey S. Sublingual immunotherapy reduces symptoms of asthma and hay fever, systematic review finds. BMJ. 2013;346:f2056.
  122. Brehler R, Klimek L, Kopp MV., Christian Virchow J. Specific immunotherapy-indications and mode of action. Deutsches Ärzteblatt International. 2013;110(9):148-58.
  123. Nelson HS. Is sublingual immunotherapy ready for use in the United States? Journal of American Medical Association. 2013;309(12):1297-8.
  124. Burks AW, Calderon  MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. Journal of Allergy and Clinical Immunology. 2013;131(5):1288-1296.e3.
  125. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in allergic rhinitis: indications, efficacy, and safety. Rhinology. 2013;51(1):9-17.
  126. Bahceciler NN, Galip N, Cobanoglu N. Multiallergen-specific immunotherapy in polysensitized patients: where are we? Immunotherapy. 2013;5(2):183-190.
  127. Purkey MT, Smith TL, Ferguson BJ, Luong A, Reisacher WR, Pillsbury HC 3rd, Toskala E. Subcutaneous immunotherapy for allergic rhinitis: an evidence based review of the recent literature with recommendations. International Forum of Allergy & Rhinology. 2013. Epub ahead of print retrieved May 13, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/?term=purkey+smith+ferguson+luong
  128. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clinical and Experimental Allergy. 2013;43(1):22-8.
  129. Wolthers OD, Host A, Frederiksen B, Halken S. Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis. Ugeskr Laeger. 2012;174(35):1989-92.
  130. Yacoub MR, Colombo G, Caminati M, Sensi L, Di Cara F, Frati F, Incorvaia C. Effects of sublingual immunotherapy on allergic inflammation: an update. Inflammation & Allergy Drug Targets. 2012;11(4):285-91.
  131. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy. 2012;67(9):1087-105.
  132. Wise SK, Schlosser RJ. Evidence-based practice: sublingual immunotherapy for allergic rhinitis. Otolaryngology Clinic of North America. 2012;45(5):1045-54.
  133. Park D, Daher N, Blaiss MS. Adult and pediatric clinical trials of sublingual immunotherapy in the USA. Expert Review of Clinical Immunology. 2012;8(6):557-64.
  134. Mailhol C, Didier A. Specific immunotherapy in grass pollen allergy. Human Vaccines and Immunotherapeutics. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23095875
  135. Moingeon P. Adjuvants for allergy vaccines. Human Vaccines and Immunotherapeutics. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23095872
  136. Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory disease. Human Vaccines and Immunotherapeutics. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23095870
  137. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon  MA. Adjuvants for immunotherapy. Current Opinions in Allergy and Clinical Immunology. 2012;12(6):648-57.
  138. Bahceciler NN. Mucosal immunity and sublingual immunotherapy in respiratory disorders. Journal of Allergy. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23028392
  139. Kroker GF, Sabnis VK, Morris MS, Thompson JC. Comment on “therapeutic effects and biomarkers in sublingual immunotherapy: a review”. Journal of Allergy. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22829847
  140. Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: An updated review. Current Opinions in Allergy and Clinical Immunology. 2012. Epub ahead of print retrieved June 19, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22622475
  141. Calderon  MA, Cox L, Casale T, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patient: looking at the published evidence. Journal of Allergy and Clinical Immunology. 2012;129(4):929-34.
  142. Paiano S. Allergen specific immunotherapy celebrated 100 years in 2011! Revue Medicale Suisse. 2012; 8(323:7-10.
  143. Valovirta E, et al. Update on current care guidelines: Allergen specific immunotherapy. Duodecim. 2012;128(1):108-9.
  144. Wise SK., Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? American Journal of Rhinology and Allergy. 2012;26(1):18-22.
  145. Hedlin G, van Hage M. The role of immunotherapy in the management of childhood asthma. Theories of Advanced Respiratory Diseases. 2012;6(13):137-46.
  146. Fugimura T, Okamoto Y, Taniguchi M. Therapeutic effects and biomarkers in sublingual immunotherapy: a review. Journal of Allergy Cairo. 2012. Epub retrieved June 19, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22500184
  147. Larenas Linnemann DE. One hundred years of immunotherapy: review of the first landmark studies. Allergy and Asthma Proceedings. 2012;33(2):122-8.
  148. Larenas-Linnemann D, Esch R., Plunkett G, Brown S, Maddox D, Barnes C, Constable D. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Annals of Allergy, Asthma & Immunology. 2011;107(5):448-58.
  149. Han DH, Rhee CS. Sublingual immunotherapy in allergic rhinitis. Asia Pacific Allergy. 2011;1(3):123-29.
  150. Calderon  MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clinical and Experimental Allergy. 2011;41(9):1263-72.
  151. Cox L, Wallace D. Specific allergy immunotherapy for allergic rhinitis: Subcutaneous and sublingual. Immunology and Allergy Clinics of North America. 2011;31(5):561-99.
  152. Calderon , M, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews. 2011;7:CD007685.
  153. Passalacqua G, Canonica GW. Sublingual immunotherapy for allergic respiratory diseases: Efficacy and safely. Immunology and Allergy Clinics of North America. 2011;31(2):265-277.
  154. Radulovic S, Wilson D, Calderon  M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740-52.
  155. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy for allergic rhinitis: an update, Current Opinion in Otolaryngology and Head and Neck Surgery. 2011;19(1):43-7.
  156. Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2011;127(1):44-5.
  157. Incorvaia C, Fuiano N, Leo G. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability. La Clinica Terapeutica. 2010;161(6):543-7.
  158. Incorvaia C, Masieri S., Berto P, Scurati S, Frati F. Specific immunotherapy by the sublingual route for respiratory allergy. Allergy Asthma and Clinical Immunology. 2010;6(1):29.
  159. Mosges R, El Hassan E, Passali D. Sublingual specific immunotherapy. Discovery Medicine. 2010; 10(53):348-54.
  160. Canonica GW, Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2010;9(37):1-2.
  161. Casale T, Stokes J. Future forms of immunotherapy. Journal of Allergy and Clinical Immunology. 2010; 10(34):1-7.
  162. Cox L., Compalati E, Canonica W. Will Sublingual Immunotherapy Become an Approved Treatment Method in the United States? Current Allergy and Asthma Reports. 2010; 11(1):4-6.
  163. Marogna M, Spadolini I, Massolo A, Canonica G, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. Journal of Allergy and Clinical Immunology. 2010;126(5):969-75.
  164. Passalaqua G, Compalati E, Canonica GW. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal 2010 Jul;3(7):216-219.
  165. Incorvaia C, Riario-Sforza G, Incorvaia S, Frati F. Sublingual immunotherapy in allergic asthma:current evidence and needs to meet. Annals of Thoracic Medicine.2010;5(3).
  166. Di Bona D, Plaia A, Scafidi V, Leto-Barone M, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and met-analysis. Journal of Allergy and Clinical Immunology. 2010;126(3):558-66.
  167. Fujimura T, Okamoto Y. Antigen-Specific Immunotherapy against Allergic Rhinitis: The State of the Art. Allergology International. 2010;59(1).
  168. Theodoropoulos D, Morris M, Morris D. Emerging concepts of sublingual immunotherapy for allergy. Drugs of Today. 2009;45(10):737-750.
  169. Thompson JC, Morris MS. Case reports by Cochard and Eigenmann. Journal of Allergy and Clinical Immunology. 2010;125:277.
  170. Canonica GW, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R, et.al. Sub-Lingual Immunotherapy World Allergy Organization Position Paper 2009. World Allergy Organization Journal. 2009.
  171. Incorvaia C, Mauro M. Do indications to sublingual immunotherapy need to be revised? Journal of Allergy and Clinical Immunology. 2010;125:277.
  172. Marseglia G, Incorvaia C, LaRosa M., Frati F, Marcucci F. Sublingual immunotherapy in children: facts and needs. Italian Journal of Pediatrics. 2009;35:31.
  173. Milgrom H, Tran ZV. Sublingual immunotherapy, meta-analysis, and knowledge in the age of information. Journal of Allergy and Clinical Immunology. 2009;124:162-3.
  174. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. Journal of Allergy and Clinical Immunology. 2009;124(1):157-61.
  175. Canonica G, Passalacqua G, Villa E, Baena-Cagnani C, Compalati E. Sublingual immunotherapy (SLIT) for House Dust Mites (HDM) in respiratory allergy: update of meta-analysis results. Journal of Allergy and Clinical Immunology. 2009;123(2):S155.
  176. Emanuel I, Parker M, Traub O. Under treatment of allergy: Exploring the utility of sublingual immunotherapy. Otolaryngology – Head and Neck Surgery. 2009;140:615-621.
  177. Krouse J. Sublingual immunotherapy for inhalant allergy: Cautious optimism. Otolaryngology – Head and Neck Surgery. 2009;140:622-624.
  178. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Current Opinion in Allergy and Clinical Immunology. 2009;9:168-76.Passalacqua G, Pawankar R, Baena-Cagnani C, Canonica G. Sublingual immunotherapy: where do we stand? Present and future. Current Opinion in Allergy and Clinical Immunology. 2009;9:1-3.
  179. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Current Opinion in Allergy and Clinical Immunology. 2008;8:585-589.
  180. Durham S. Sublingual immunotherapy: what have we learnt from the ‘big trials’? Current Opinion in Allergy and Clinical Immunology. 2008;8:577-584.
  181. Gerth van Wijk R. When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies. Current Opinion in Allergy and Clinical Immunology. 2008;8:565-570.
  182. Rodriguez-Perez N, Penagos M, Portnoy JM. New Types of Immunotherapy in Children. Current Allergy and Asthma Reports. 2008;8:484-492.
  183. Cox L. Sublingual Immunotherapy and Allergic Rhinitis. Current Allergy and Asthma Reports. 2008;8:102-110.
  184.  Mondello W. Hope for the food allergic: New research may lead to a cure. Living Without, editorial. 2008;Oct-Nov Issue:22-28.
  185.  Morogna M. Preventative effects of sublingual immunotherapy in childhood: An open randomized controlled study. Annals of Allergy, Asthma, and Immunotherapy. 2008;101:206-211.
  186. Larenas-Linnemann D. Sublingual immunotherapy: Dosing in relation to clinical and immunological efficacy. Allergy and Asthma Proceedings. 2008;29(2):130-138.
  187. Canonica W, Passalacqua G. Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. World Allergy Organization Journal. April 2008:70-72.
  188. Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens J, Togias T, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2 LEN* and AllerGen**). Allergy. 2008;63(86):8-160.
  189. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani C, Orozco S, Pedroza A, et al. Meta-analysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. Chest. 2008;133:599-609.
  190. Cox L. Sublingual Immunotherapy in Pediatric Allergic Rhinitis and Asthma: Efficacy, Safety, and Practical Considerations. Pediatric Allergy and Immunology. 2007;7:410-420.
  191. Didier A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. American Academy of Allergy, Asthma & Immunology. October2007:1-8.
  192. Cox L, Li JT, Nelson HS, et al. Allergen Immunotherapy: a practice parameter second update. Journal of Allergy & Clinical Immunology. 2007 Sep;120(3Suppl):S25-85.
  193. Pondrom S. Sublingual Immunotherapy (SLIT) Quality of Life Outcomes. COSM 2007: American Rhinologic Society. 2007;2(8):24-25.
  194. Cox L. Sublingual immunotherapy, part 2: Safety and practical considerations. The Journal of Respiratory Disease. June 2007;6:237-243.
  195. Tahamiler R, Gkioukixel S, Canakcioglu S. Long-Term Efficacy of Sublingual Immunotherapy in Patients With Perennial Rhinitis. The Laryngoscope. 2007;117:965-969.
  196. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (Grazax) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. Clinical and Experimental Allergy. 2007;37:772-779.
  197. Pham-Thi N, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatric Allergy and Immunology. 2007;18:47-57.
  198. Bonds RS, et al. Allergic Disorders: When Should You Consider Immunotherapy? Consultant. 2007;47( 4):405-412.
  199. Cox L. Sublingual immunotherapy, part 1: Review of Clinical Efficacy. The Journal of Respiratory Diseases. 2007;28(4):162-168.
  200. Nelson HS. Allergen immunotherapy: Where is it now? Journal of Allergy and Clinical Immunology. 2007;119( 4):769-779.
  201. Durham S. Tradition and innovation: Finding the right balance. Journal of Allergy and Clinical Immunology. 2007;119( l4):792-795.
  202. Pajno G. Sublingual immunotherapy: The optimism and the issues. Journal of Allergy and Clinical Immunology. 2007;119( 4):796-801.
  203. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2007;119(4):872-880.
  204. Passalacqua G, et al. Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2007;119(4):881-891.
  205. Leatherman B, et al. Sublingual Immunotherapy: Past, present, paradigm for the future? A review of the literature. Otolaryngology-Head and Neck Surgery. 2007;136:S1-S20.
  206. Marogna M, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Annals of Allergy, Asthma & Immunology. 2007;98:274-280.
  207. Finegold I. Allergen immunotherapy; Present and future. Asthma and Allergy Proceedings. 2007;28(1):44-49.
  208. Bellanti J, Settipane R. Sublingual immunotherapy: A procedure whose time has come? Asthma and Allergy Proceedings. 2007;28(1), pages 1-2, January-February 2007.
  209. Marogna M, et al. Long-Lasting Effects of Sublingual Immunotherapy for House Dust Mites in Allergic Rhinitis with Bronchial Hyperreactivity: A Long-Term (13-Year) Retrospective Study in Real Life. International Archives of Allergy & Immunology. 2006;142(1):70-78.
  210. Passalacqua G, Canonica GW. Sublingual immunotherapy:update 2006. Current Opinion in Allergy and Clinical Immunology. 2006;6:449-454.
  211. Werner-Klein M. Sublingual immunotherapy of allergic diseases. Expert Opinion in Drug Delivery. 2006;3(5):599-612.
  212. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61(10):1162-72.
  213. Berto P, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Annals of Allergy, Asthma and Immunology. 2006;97:615-621.
  214. Passalacqua G, et al. New Insights in Sublingual Immunotherapy. Current Allergy and Asthma Reports. 2006;6:407-412.
  215. McEldowney SJ, et al. Pollen Immunotherapy: Selection, Prevention, and Future Directions. Current Allergy and Asthma Reports. 2006;4:420-426.
  216. Bousquet J. Sublingual Immunotherapy: Validated! Allergy. 2006;61( S81)
  217. Burastero S. E. Sublingual immunotherapy for allergic rhinitis: an update. Current Opinion in Otolaryngology & Head and Neck Surgery. 2006;14:197-201.
  218. Didier A. Future developments in sublingual immunotherapy. Allergy. 2006;61(Suppl. 81):29-31.
  219. Malling HJ. Sublingual immunotherapy: efficacy – methodology and outcome of clinical trials. Allergy. 2006;61(Suppl. 81):24-28.
  220. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy. 2006;61(Suppl. 81):15-19.
  221. Passalacqua G, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61:849-854.
  222. Canonica GW, Passalacqua G. Sublingual Immunotherapy in the Treatment of Adult Allergic Rhinitis Patients. Allergy. 2006;61:20.
  223. Pham-Thi N, et al. Sublingual immunotherapy in the treatment of children. Allergy. 2006;61 (Suppl. 81):7-10.
  224. Ortolani C, et al. Practice parameters for sublingual immunotherapy. Monaldi Archives for Chest Disease. 2006;65(1):44-6.
  225. Guerra L, et al. Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergologia et immunopathologia. 2006;34(02):82-83.
  226. Mascarell L, et al. Novel Ways for Immune Intervention in Immunotherapy:Mucosal Allergy Vaccines. Immunology and Allergy Clinics of North America. 2006;26:283-306.
  227. Cox L, et al. Sublingual immunotherapy: A comprehensive review. Journal of Allergy and Clinical Immunology. 2006; 117(5):1021-1035.
  228. Nelson H. Advances in upper airway diseases and allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2006;117(5):1047-1053.
  229. Durham S, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2006;117(4):802-809.
  230. Passalacqua G, et al. Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. Inflammation & Allergy – Drug Targets. 2006;5:43-51.
  231. Passalacqua G, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). Journal of Allergy and Clinical Immunology. 2006;117(4).
  232. Potter P. Update on sublingual immunotherapy. Annals of Allergy, Asthma and Immunology. 2006;96(Suppl 1):S22-S25.
  233. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy. 2006;61:149-150.
  234. Dahl R, et al. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61:185-190.
  235. Cingi C, et al. Efficacy of long-term sublingual-oral immunotherapy in allergic rhinitis. ACTA Otorhinolaryngol Italica. 2005;25:214-219.
  236. Marogna M, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. Journal of Allergy and Clinical Immunology. 2005;115(6):1184-1188.
  237. Gidaro GB, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clinical & Experimental Allergy. 2005;35:565-571.
  238. Pajno G. Allergen immunotherapy in early childhood: between Scylla and Charybdis Clinical & Experimental Allergy. 2005;35:551-553.
  239. Courtney AU, et al. Childhood Asthma: Treatment Update. American Family Physician. 2005;71(10):1959-1968.
  240. Parks K. Advances in Immunotherapy: Current Considerations and Beyond. The Allergy and Immunology Report. 2005;1(2).
  241. Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy. 2005;60:1-3.
  242. Lambrecht BN. Dendritic cells in the pathogenesis of asthma. Clinical and Experimental Allergy. 2004;4:123-128
  243. Nelson H. Advances in upper airway diseases and allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2004;113(4):635-42.
  244. Passalacqua G, et al. Efficacy and safety of sublingual immunotherapy. Annals of Allergy, Asthma, and Immunology. 2004;93(1):3-12.
  245. Portnoy J. Allergen Immunotherapy in the Prevention of Asthma. Current Opinion Allergy Clinical Immunology, 2004;4(2):131-136.
  246. Passalacqua G, Canonica GW. Sublingual or injection immunotherapy: the final answer? Allergy. 2004;59:37-38.
  247. Malling HJ. Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Current Opinion in Allergy and Clinical Immunology. 2004;4:539-542.
  248. Mosages R. The role of hyposensitization: do we need to start rethinking? Clinical Opinion in Allergy and Clinical Immunology. 2004;4:155-157.
  249. Norman P S. Immunotherapy: 1999-2004. Journal of Allergy and Clinical Immunology. 2004;113(6):1013-1023.
  250. Passalacqua G, Lombardi C, Canonica GW. Sublingual Immunotherapy:An Update. Current Opinion in Allergy and Clinical Immunology. 2004;4(1).
  251. Markert UR, Elsner P. Local Immunotherapy in Allergy. Chemical Immunology and Allergy. (Lead chapter by D. Morris, et al). 2003;Vol. 82, Karger, Basel, Switzerland.
  252. Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis. (Cochrane Review), The Cochrane Library, Issue 2. 2003.
  253. Canonica GW, Passalacqua G. Non-injection routes for immunotherapy. Journal of Allergy and Clinical Immunology. 2003;111(3):437-448.
  254. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2003;111(3):S793-798.
  255. Di Rienzo V, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10 year prospective study. Clinical and Experimental Allergy. 2003;33:206-210.
  256. Bielory L, Heimall J. Review of complementary and alternative medicine in treatment of ocular allergies. Current Opinion in Allergy and Clinical Immunology. 2003; 3:395-399.
  257. Passalacqua G, Baena-Cagnani C, Berardi M, Canonica GW. Oral and sublingual immunotherapy in pediatric patients. Current Opinion in Allergy and Clinical Immunology. 2003;3(2):139-145.
  258. Li J, et al. Allergen immunotherapy: a practice parameter. Journal of Allergy and Clinical Immunology. 2003;90:27.
  259. Kagi MK, Wuthrich B. Different methods of local allergen-specific immunotherapy. Allergy. 2002;57:379-388.
  260. Reiber ME. Sublingual Administration of Allergen Desensitization. Tennessee Medicine. 2002:465-467.
  261. Douglass J, O’Hehir R. Specific allergen immunotherapy: time for alternatives? Clinical and Experimental Allergy. 2002;32:1-3.
  262. Bousquet J. The new ARIA guidelines: putting science into practice, Clinical and Experimental Allergy Review. 2002;2:38-43.
  263. Volpe Della A, et al. Sublingual Allergen-Specific Immunotherapy in Allergic Rhinitis and Related Pathologies: Efficacy in a Pediatric Population. International Journal of Immunopathology and Pharmacology. 2002;15(1):35-40.
  264. Malling H. Is Sublingual Immunotherapy Clinically Effective? Current Opinion Allergy and Clinical Immunology. 2002;2(6):523-532.
  265. Allergic Rhinitis and its impact on Asthma (ARIA) Workshop Report. Journal of Allergy and Clinical Immunology. 2001;108(5).
  266. Bousquet J. ARIA Workshop Group Guidelines. Journal of Allergy and Clinical Immunology. 2001:S242-S245.
  267. Passalacqua G, Canonica GW. Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. BioDrugs. 2001;15(8):509-519.
  268. Morris DL. Current use of sublingual-swallow immunotherapy. Current Opinion in Otolaryngology & Head and Neck Surgery. 2001;9(3):179-180.
  269. Marogna M, et al. Clinical Practice Improvement Program for Immunotherapy of Respiratory Allergic Diseases. International Journal of Immunopathology and Pharmacology. 2001;14(2):93-101.
  270. Theodorpoulos D, Lockey R. Allergen Immunotherapy: Guidelines, Update and Recommendations of the World Health Organization. Allergy and Asthma Proceedings. 2000;21(3):159-66.
  271. Frew A, et al. Sublingual Immunotherapy. Journal of Allergy Clinical Immunology. 2001:441-444.
  272. Brown JL, Frew AJ. The efficacy of oromucosal immunotherapy in respiratory allergy. Clinical & Experimental Allergy. 2001;21(1):8-10.
  273. Rakoski J, Wessner D. A Short Assessment of Sublingual Immunotherapy. International Archives of Allergy and Immunology. 2001;126:185-187.
  274. Pineda-Algorta J, et al. Study of the efficacy of sublingual immunotherapy in patients with grass pollen sensitization: Mini Symposium 3 Sublingual Immunotherapy. Allergy. 2000;63(55):24.
  275. Ano-Garcia M, et al. Efficacy and safety of sublingual immunotherapy in patients with sensitization to Dermtophagoides pteronyssinus: Mini Symposium 3 Sublingual Immunotherapy. Allergy. 2000;55(63):24.
  276. Khinchi MS, et al. Clinical efficacy of sublingual-swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen: Mini Symposium 3 Sublingual Immunotherapy. Allergy. 2000;63(55):24.
  277. Donato RM. Patients with allergic rhinitis from Argentine treated with SLIT (sublingual immunotherapy) a non-injective route. Abstract presented October 2000 IACAI Conference
  278. Malling HJ. Allergen-specific immunotherapy. Present state and directions for the future. Allergy. 1999;54:30-33.
  279. Passalacqua G, et al. Oral and Sublingual Immunotherapy: General Aspects and Critical Considerations. WMW Themenheft:Hyposensibilsierung. 1999;433-437.
  280. Donahue JG, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Annals of Allergy, Asthma and Immunology. 1999;82:339-347.
  281. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization Position Paper Allergy. 1998;53(44):1-29.
  282. Malling HJ. Sublingual Immunotherapy. Clinical Experimental Allergy. 1996; 26:1228-1231.
  283. Passalacqua G, Canonica GW. Alternative routes for allergen-specific immunotherapy. Journal of Investigational Allergology and Clinical Immunology. 1996;6(2):81-87.
  284. Creticos PS. A review of oral specific immunotherapy: Expressions on allergen specific immunotherapy. Stallergenes S.A. 1995;1. (US Based DBPC Study).

2. Studies/Abstracts

  1. Yang Y, Zhou W, Chen A. Efficacy of sublingual immunotherapy for cedar pollinosis: A systematic review and meta-analysis. Annals of Allergy, Asthma & Immunology. 2016 Oct;117(4):348-353. doi: 10.1016/j.anai.2016.07.024.
  2. Nolte H, Plunkett G, Grosch K, et al. Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions. Annals of Allergy, Asthma & Immunology. 2016 Sep;117(3):298-303. doi: 10.1016/j.anai.2016.07.004.
  3. Nucera E, Aruanno A, Rizzi A, et al. Profilin desensitization: A case series. International Journal of Immunopathology and Pharmacology. 2016 Sep;29(3):529-36. doi: 10.1177/0394632015621926.
  4. Sakurai D, Yonekura S, Iinuma T, et al. Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. Rhinology. 2016 Sep;54(3):221-30. doi: 10.4193/Rhin15.223.
  5. Commins SP, Kim EH, Orgel K, Kulis M. Peanut allergy: New developments and clinical implications. Current Allergy and Asthma Reports. 2016 May;16(5):35. doi: 10.1007/s11882-016-0613-x. [Epub ahead of print]
  6. Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA. 2016 Apr 26;315(16):1715-25. doi: 10.1001/jama.2016.3964. [Epub ahead of print]
  7. Sakurai D, Yonekura S, Iinuma T, et al. Sublingual immunotherapy for allergic rhinitis: Subjective versus objective tools to evaluate its success. Rhinology. 2016 Apr 23. Epub ahead of print retrieved April 26, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/27107025
  8. Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cellular & Molecular Immunology. 2016 Apr 11. doi: 10.1038/cmi.2016.14. [Epub ahead of print]
  9. Theodoropoulos DS, Stockdale CK, Duquette DR, Morris MS. Inhalant allergy compounding the chronic vaginitis syndrome: Characterization of sensitization patterns, comorbidities and responses to sublingual immunotherapy. Archives of Gynecology and Obstetrics. 2016 Apr 4. Epub ahead of print retrieved April 19, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/27040422
  10. Klimek L, Mosbech H, Zieglmayer P, Rehm D, Stage BS, Demoly P. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Review of Clinical Immunology. 2016 Apr;12(4):369-377. doi: 10.1586/1744666X.2016.1144473. Epub 2016 Feb 11.
  11. Larenas-Linnemann D. Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis. Annals of Allergy, Asthma & Immunology. 2016 Apr;116(4):274-286. doi: 10.1016/j.anai.2016.02.008. [Epub ahead of print]
  12. Vesna TS, Denisa D, Slavenka J, et al. Efficacy of sublingual Immunotherapy with Dermatophagoides pteronyssinus: A real-life study. Iranian Journal of Allergy, Asthma and Immunology. 2016 Apr;15(2):112-121. Epub ahead of print retrieved April 21, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/27090364
  13. Maloney J, Berman G, Gagnon R, et al. Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. Journal of Allergy and Clinical Immunology: In Practice. 2016 Mar-Apr;4(2):301-309.e2. doi: 10.1016/j.jaip.2015.11.004. Epub 2016 Jan 2.
  14. Horn A, Zeuner H, Wolf H, et al. Health-related quality of life during routine treatment with the SQ-standardised grass allergy immunotherapy tablet: A non-interventional observational study. Clinical Drug Investigation. 2016 Mar 15. doi: 10.1007/s40261-016-0388-9. [Epub ahead of print]
  15. Jerzynska, J, Stelmach W, Rychlik B, Lechańska, J, Podlecka D, Stelmach I. The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis. Allergy and Asthma Proceedings. 2016 Mar;37(2):105-114. doi: 10.2500/aap.2016.37.3921. [Epub ahead of print]
  16. Soh JY, Thalayasingam M, Ong S, Loo EX, Shek LP, Chao SS. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period. The Journal of Laryngology & Otology. 2016 Mar;130(3):272-277. doi: 10.1017/S0022215116000025. Epub 2016 Jan 19.
  17. Reisacher WR, Suurna MV, Rochlin K, Bremberg MG, Tropper G. Oral mucosal immunotherapy for allergic rhinitis: A pilot study. Journal of Allergy & Rhinology. 2016 Jan;7(1):21-28. doi: 10.2500/ar.2016.7.0150. [Epub ahead of print]
  18. Demoly P, Passalacgua, G, Calderon MA, Yalaoui T. Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose. Clinical and Translational Allergy. 2015 Dec 23;5:44. doi: 10.1186/s13601-015-0088-1. eCollection 2015.
  19. Steveling EH, Lao-Araya M, Koulias C, et al. Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes. Clinical and Translational Allergy. 2015 Dec 17;5:43. doi: 10.1186/s13601-015-0087-2. eCollection 2015.
  20. Yuta, A, Ogawa Y, Suzuki Y, et al. Clinical efficacy of sublingual immunotherapy for Japanese cedar pollinosis in the first follow-up year. Japanese Journal of Allergology. 2015 Dec;64(10):1323-1333. doi: 10.15036/arerugi.64.1323. [Epub ahead of print]
  21. Chen Z, Qian Y, Liu S, et al. Onset time and efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in children with allergic rhinitis. Chinese Journal of Otorhinolaryngology Head and Neck Surgery. 2015 Aug;50(8):622-626. Epub ahead of print retrieved April 26, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/26696197
  22. Chen S, Zeng X, Wang L, et al. Effects of house dust mite sublingual immunotherapy in children with allergic rhinitis and asthma. Chinese Journal of Otorhinolaryngology Head and Neck Surgery. 2015 Aug;50(8):627-631. Epub ahead of print retrieved April 26, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/26696198
  23. Leonardi S, Castro A, Lanzafame A, et al. Safety and efficacy of sublingual specific immunotherapy to house dust mite using a different dosage: A pilot study. Journal of Biological Regulators & Homeostatic Agents. 2015 Apr-Jun;29(2 Suppl 1):84-8. [Epub ahead of print]
  24. Karakoc-Aydiner E, Eifan AO, Baris S, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: A 3-year prospective randomized controlled trial. Journal of Investigational Allergology and Clinical Immunology. 2015;25(5):334-42. Epub ahead of print retrieved April 26, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/26727762
  25. Shah-Hosseini K, Mioc K, Hadler M, Karagiannis E, Mösges R. Optimum treatment strategies for polyallergic patients – analysis of a large observational trial. Current Medical Research and Opinion. 2015 Dec;31(12):2249-59. doi: 10.1185/03007995.2015.1094653. Epub 2015 Oct 6.
  26. Lin Z, Liu Q, Li T, Chen D, Chen D, Xu R. The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration. International Forum of Allergy & Rhinology. 2015 Nov 17. doi: 10.1002/alr.21657. [Epub ahead of print]
  27. Moreno Benítez F, Espinazo Romeu M, Letran Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation in allergen content in sublingual allergen immunotherapy with house dust mites. Allergy. 2015 Nov;70(11):1413-20. doi: 10.1111/all.12694. Epub 2015 Sep 11.
  28. Nolte M, et al. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet. Annals of Allergy, Asthma & Immunology. 2015 Oct 21. doi: 10.1016/j.anai.2015.09.018. [Epub ahead of print]
  29. Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: A clinical trial. Allergy. 2015 Oct 14. doi: 10.1111/all.12791. [Epub ahead of print]
  30. Katotomichelakis M, et al. Smoking effects on quality of life of allergic rhinitis patients after sublingual immunotherapy. Rhinology. 2015 Sep 12. Epub ahead of print retrieved November 23, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26362673
  31. Pfaar O, et al. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy. 2015 Sep 3. doi: 10.1111/all.12760. [Epub ahead of print]
  32. Murakami D, et al. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study. Auris Nasus Larynx. 2015 Jul 18. pii: S0385-8146(15)00169-8. doi: 10.1016/j.anl.2015.06.011. [Epub ahead of print]
  33. Barberi S, et al. Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. Asia Pacific Allergy. 2015 Jul;5(3):163-9. doi: 10.5415/apallergy.2015.5.3.163. Epub 2015 Jul 29.
  34. Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy. 2015 May 22;5:12. doi: 10.1186/s13601-015-0057-8. eCollection 2015.
  35. Huang S, et al. Study on the efficacy and safety of sublingual immunotherapy with standardized dermatophagoides farinae drops for allergic rhinitis. Journal of clinical otorhinolaryngology, head, and neck surgery. 2015 Apr;29(7):618-21. Retrieved December 4, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26201187
  36. Hu X, et al. Efficacy of sublingual immunotherapy with Dermatophagoides farinae drops on patients with allergic rhinitis of different symptom severity. Journal of clinical otorhinolaryngology, head, and neck surgery. 2015 Feb;29(3):223-5. Retrieved December 7, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26012292
  37. Pfaar O, Richter HG, Klimek L, Sieber J, Hadler M, Karagiannis E. Sublingual immunotherapy with a five-grass pollen tablet in adult patients with allergic rhinitis: An open, prospective, noninterventional, multicenter study. BioMed Research International. 2015;2015:584291. doi: 10.1155/2015/584291. Epub 2015 Aug 16.
  38. Okamoto Y, et al. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. International Archives of Allergy and Immunology. 2015;166(3):177-88. doi: 10.1159/000381059. Epub 2015 Apr 18.
  39. Kruse K1, Gerwin E, Eichel A, Shah-Hosseini K, Mosges R. Conjunctival provocation tests: A predictive factor for patients seasonal allergic rhinoconjunctivitis symptoms. The Journal of Allergy and Clinical Immunology, in Practice.. 2015 May-Jun;3(3):381-6. doi: 10.1016/j.jaip.2014.10.015. Epub 2015 Jan 22.
  40. Incorvaia C1, Ridolo E. In the strategies to prevent asthma exacerbations, allergic asthma needs specific treatment. Current Medical Research and Opinion. 2015 Apr;31(4):821-3. doi: 10.1185/03007995.2015.1024215. Epub 2015 Mar 19.
  41. Shamji MH1, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. Journal of Allergy & Immunology. 2015 Apr;135(4):913-921.e9. doi: 10.1016/j.jaci.2014.09.049. Epub 2014 Nov 22.
  42. Potter PC1, Baker S, Fenemore B, Nurse B. Clinical and cytokine responses to house dust mite sublingual immunotherapy. Annals of Allergy, Asthma & Immunology. 2015 Apr;114(4):327-34. doi: 10.1016/j.anai.2014.12.015. Epub 2015 Feb 3.
  43. Liu L1, et al. The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clinical and Experimental Allergy. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417.
  44. Mascarell L1, et al. Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells. Allergy. 2015 Apr;70(4):408-19. doi: 10.1111/all.12576.
  45. Park KH1, et al. In vitro evaluation of allergen potencies of commercial house dust mite sublingual immunotherapy reagents. Allergy Asthma Immunology Research. 2015 Mar;7(2):124-9. doi: 10.4168/aair.2015.7.2.124. Epub 2014 Dec 18.
  46. Maloney J1, et al. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. Allergy. 2015 Mar;70(3):302-9. doi: 10.1111/all.12560. Epub 2015 Jan 14.
  47. Ciprandi, G. A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy. Journal of Asthma & Allergy. 2015 Mar 6;8:25-7. doi: 10.2147/JAA.S82077. eCollection 2015.
  48. Theodoropoulos DS, Morris MS, Morris DL. Sustained improvement of psoriatic lesions in the course of sublingual immunotherapy for airborne allergens; clinical evidence of cross-tolerance. European Review for Medical and Pharmacological Sciences. 2015;19(3):392-5.
  49. Senti G1, Kundig T. Intralymphatic immunotherapy. World Allergy Organization Journal. 2015 Mar 7;8(1):9. doi: 10.1186/s40413-014-0047-7. eCollection 2015.
  50. De Rienzo V, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Annals of Allergy, Asthma & Immunology. 2014 Dec;113(6):671-673.e1. doi: 10.1016/j.anai.2014.09.009. Epub 2014 Oct 7.
  51. Nolte H1, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Journal of Allergy and Clinical Immunology. 2015 Jan 27. pii: S0091-6749(14)03711-7. doi: 10.1016/j.jaci.2014.12.1911. [Epub ahead of print]
  52. Hou B1, Murata M, Said AS, Sakaida H, Masuda S, Takahashi T, Zhang Z, Takeuchi K. Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy. Allergy & Rhinology (Providence, RI). 2015 Jan;6(1):33-8. doi: 10.2500/ar.2015.6.0107. Epub 2015 Feb 11.
  53. Kei-ichi Y, et al. Immunological parameters in prophylactic sublingual immunotherapy in asymptomatic subjects sensitized to Japanese cedar pollen. Allergology International. 2015 Jan;64(1):54-9. doi: 10.1016/j.alit.2014.07.001. Epub 2014 Oct 20.
  54. Eberle P1, Brueck H, Gall R, Hadler M, Sieber J, Karagiannis E. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents. Pediatric Allergy and Immunology. 2014 Dec;25(8):760-6. doi: 10.1111/pai.12298. Epub 2014 Dec 29.
  55. Ding LF1, et al. Effects of sublingual immunotherapy on serum IL-17 and Il-35 levels in children with allergic rhinitis or asthma. Zhongguo Dang Dai Er Ke Za Zhi. 2014 Dec;16(12):1206-10.
  56. Serrano E1, Wahn HU, Didier A, Bachert C. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis. American Journal of Rhinology & Allergy. 2014 Nov-Dec;28(6):471-6. doi: 10.2500/ajra.2014.28.4112. Epub 2014 Oct 2
  57. [The effect and the analysis of the influence factors of sublingual immunotherapy on patients with pharyngitis and allergy to house dust mite]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Oct;28(19):1511-3. (No authors listed)
  58. Hebert J1, et al. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. Allergy, Asthma & Clinical Immunology. 2014 Oct 30;10(1):53. doi: 10.1186/1710-1492-10-53. eCollection 2014.
  59. Cingi C1, et al. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. European Archives of Oto-Rhino-Larynogology. 2014 Dec 17. [Epub ahead of print].
  60. Winterroth LC, Williams PV. Efficacy and Safety of Grass Sublingual Immunotherapy Tablet, MK-7243: a Large Randomized Controlled Trial. Pediatrics. 2014;134:S161DOI: 10.1542/peds.2014-1817XX.
  61. Gorelik M1, Narisety SD, Guerrerio AL, Chichester KL, Keet CA, Bieneman AP, Hamilton RG, Wood RA, Schroeder JT, Frischmeyer-Guerrerio PA. Suppression of the immunologic response to peanut during immunotherapy is often transient. Journal of Allergy & Clinical Immunology. 2014 Dec 24. pii:S0091-6749(14)01646-7. doi: 10.1016/j.jaci2014.11.010 [epub ahead of print]
  62. Franco F1, et al. New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. Biologics. 2014 Sep 12;8:221-6. doi: 10.2147/BTT.S50951. eCollection 2014.
  63. Wang C1, Zhang L. Specific immunotherapy for allergic rhinitis in children. Current Opinion in Otolaryngology & Head and Neck Surgery. 2014 Sep 9. [Epub ahead of print]
  64. Mosbech H1, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2014 Sep;134(3):568-575.e7. doi: 10.1016/j.jaci.2014.03.019. Epub 2014 May 3.
  65. Calderon  MA1, Berstein DI, Blaiss M, Anderssen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. Clinical & Experimental Allergy. 2014 Oct;44(10):1228-39. doi: 10.1111/cea.12331.
  66. Irani C, Saleh RA, Jammal M, Haddad F. High-dose sublingual immunotherapy in patients with uncontrolled allergic rhinitis sensitized to pollen: a real-life clinical study. International Forum of Allergy and Rhinology. 2014 Oct;4(10):802-7. doi: 10.1002/alr.21375. Epub 2014 Sep 15.
  67. Bozek A1, Kolodziejczyk K, Warkocka-Szoltysek B, Jarzab J. Grass pollen sublingual immunotherapy: A double-blind, placebo controlled study in elderly patients with seasonal allergic rhinitis. American Journal of Rhinology and Allergy. 2014 Sep-Oct;28(5):423-7. doi: 10.2500/ajra.2014.28.4091.
  68. Liu L1, et al. The Efficacy of Sublingual Immunotherapy with Dermatophagoides farina Vaccine in a Murine Atopic Dermatitis Model. Clinical & Experimental Allergy. 2014 Sep 25. doi: 10.1111/cea.12417. [Epub ahead of print]
  69. Wang L1, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy. 2014 Sep;69(9):1181-8. doi: 10.1111/all.12188. Epub 2014 Jul 24
  70. Zhang C1, Ohno T, Kang S, Takai T, Azuma M. Repeated antigen painting and sublingual immunotherapy in mice convert sublingual dendritic cell subsets. Vaccine. 2014 Sep 29;32(43):5669-76. doi:10.1016/j.vaccine.2014.08.013. Epub 2014 Aug 29.
  71. Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Review of Vaccines. 2014 Sep 4:1-11. [Epub ahead of print]
  72. Muñoz-Wolf N1, Rial A, Saavedra JM, Chabalgoity JA. Journal of Visualized Experiments. 2014 Aug 30;(90). doi:10.3791/52036.
  73. de Blay F1, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial. Respiratory Medicine. 2014 Aug 7. pii:S0954-6111(14)00276-5. doi:10.1016/j.rmed.2014.07.017. [Epub ahead of print]
  74. Luo R1, et al. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy. European Journal of Pediatrics. 2014 Aug;173(8):1033-40. doi:10.1007/s00431-014-2287-5. Epub 2014 Mar 4.
  75. Kralimarkova TZ1, et al. Objective approach for fending off the sublingual immunotherapy placebo effect in subjects with pollenosis: double-blinded, placebo-controlled trial. Annals of Allergy, Asthma & Immunology. 2014 Jul;113(1):108-13. doi:10.1016/j.anai.2014.03.019. Epub 2014 Apr 16.
  76. [No authors listed]. Sublingual immunotherapy for allergic rhinitis. The Medical Letter on Drugs and Therapeutics. 2014 Jun 9;56(1444):47-8.
  77. Poole, CD1, Bannister, CA, Norgaard Andreasen J, Strodl Andersen, J, Currie, CJ. Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. Health and Quality of Life Outcomes. 2014 Jun 13;12:99. doi: 10.1186/1477-7525-12-99.
  78. Quin YE1, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farina drops in patients with atopic dermatitis. International Journal of Dermatology. 2014 May;53(5):650-5. doi:10.1111/ijd.12302. Epub 2013 Aug 22.
  79. Devillier P1, Dreyfus JF, Demoly P, Calderon  MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Medicine. 2014 May 1;12:71. doi: 10.1186/1741-7015-12-71.
  80. Durham SR1, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy. 2014 May;69(5):617-23. doi:10.1111/all.12373. Epub 2014 Mar 10
  81. Trebuchon, F1, Lheritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clinical and Translational Allergy. 2014 Apr 29;4:15. doi: 10.1186/2045-7022-4-15. eCollection 2014
  82. Tian M1, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(=) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. International Forum of Allergy & Rhinology. 2014 May;4(5):371-5. doi:10.1002/alr.21305. Epub 2014 Mar 3.
  83. Sato S1, et al. Clinical studies in oral allergen-specific immunotherapy: differences among allergens. Internation Archives of Allergy and Immunology. 2014;164(1):1-9. doi:10.1159/0000361025. Epub 2014 Apr 29.
  84. Chen BY, Long ZXM, Huang YJ, Zeng JM. [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in monosensitized and polysensitized patients with allergic rhinitis] [Article in Chinese]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. [Chinese Journal of Otorhinolaryngology Head and Neck Surgery]. 2013 Jul;48(7):549-554.
  85. Marogna M., Braidi C, Bruno ME, Colombo C, Colombo F, Massolo A, Palumbo L, Compalati E. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial. Allergologia et Immunopathologia. 2014 Jul-Aug;41(4):216-224.0
  86. De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, Casatagna G, Giancane G, Duse M. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children’s real life. European Review for Medical and Pharmacological Sciences. 2013 Aug;17(16):2225-2231.
  87. Quin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides Farinae Drops in children with atopic dermatitis. International Journal of Dermatology. 2014 May;53(5):650-655.
  88. Tian M, Lu YQ, Wang Y, Jiang YH, Zhao DY. Long-term efficacy of sublingual immunotherapy with Dermatophagoides Farinae Drops in children with allergic asthma sensitized to dust mites]. [Article in Chinese]. Zhonghua Er Ke Za Zhi. [Chinese Journal of Pediatrics]. 2013 Oct;51(10):741-744.
  89. Chen S, Wang L, Liao F, Zeng X, Xing QB, Chen B, Lin XZ. [Efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in preschool and school-age children with allergic asthma and allergic rhinitis]. [Article in Chinese]. Zhonghua Er Ke Za Zhi. [Chinese Journal of Pediatrics]2014 Nov;51(11):831-835.
  90. Queirós MG, Silva DA, Siman IL, Ynoue LH, Araújo NS, Pereira FL, Almeida KC, Miranda JS, Pena JD, Cunha-Junior JP, Taketomi EA. Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children. Pediatric Allergy and Immunology. 2013 Dec;24(8):752-761.
  91. Creticos PS, Esch RE, Couroux P, Gentile D, D’Angelo P, Whitlow B, Alexander M, Coyne TC Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2014 Mar,133(3):751-758.
  92. Sikora JM, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Annals of Allergy, Asthma & Immunology. 2013;110(3):194-197.
  93. Baiardini I, Puggioni F, Menoni S, Boot JD, Diamant Z, Braido F, Canonica GW. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respiratory Medicine. 2013;107(3):361-7.
  94. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clinical Experimental Allergy. 2013;43(2):242-8.
  95. Wang DH, Chen L, Cheng L, Li KN, Yuan H, Lu JH, Li H. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23616386
  96. Creticos PS, Maloney J, Bernstei, DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nekam K, Nolte H. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. Journal of Allergy and Clinical Immunology. 2013;131(5):1342-1349.
  97. Marogna M, Braidi C, Bruno ME, Colombo C, Colombo F, Massolo A, Palumbo L, Compalati E. The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: A real-life randomised trial. Allergologia et Immunopathologia. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23141837
  98. Mun SJ, Shin JM, Han DH, Kim JW, Kim DY, Lee CH, Min YG, Rhee CS. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis. International Forum of Allergy Rhinology. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23044892
  99. Zheng BQ, Wang GL, Yang S. Efficacy of specific sublingual immunotherapy with dermatophagoides farinae drops in the treatment of cough variant asthma in children. Zhongguo Dang Dai Er Ke Za Zhi. 2012;14(8):585-8.
  100. Nayak AS, Atiee GJ, Dige E, Maloney J, Nolte H. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy and Asthma Proceedings. 2012; 33(5):404-10.
  101. Wessel F, Chartier A, Meunier, JP., Magnan, A. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons – the GRAAL trial. Clinical Drug Investigation. 2012;32(7):451-63.
  102. Batard T, Zimmer A, Nony E, Bouley J, Airouche S, Luce S, Turfkruyer M, Tourdot S, Mascarell L, Moingeon P. Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation. Vaccine. 2012;30(38):5666-74.
  103. Panjo GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T, Valenzise M, Passalacqua G. Adherence to sublingual immunotherapy in preschool children. Pediatric Allergy and Immunology. 2012;23(7):688-9.
  104. Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, Eberle P, Bufe A. SLIT Study Group. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology. 2012;130(4):886-93.
  105. Han DH, Choi YS, Lee JE, Kim DY, Kim JW, Lee CH, Rhee CS. Clinical efficacy of sublingual immunotherapy in pediatric patients with allergic rhinitis sensitized to house dust mites:Comparison to adult patients. Acta Oto-largnologica. 2012;132 Suppl 1:S88-93.
  106. Bordas-Le Floch V, Bussieres L, Airouche S, Lautrette A, Bouley J, Berjont N, Horiot S, Huet A, Jain K, Limoine P, Chabre H, Batard T, Mascarell L, Baron-Bodo V, Tourdot S, Nony E, Moingeon P. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. International Archives of Allergy and Immunology. 2012;158(2):157-67.
  107. Vanbervliet B, Tourdot S, Mascarell L, Rouzaire P, Vocanson M, Rozieres A, Benetiere J, Moingeon P, Nicolas JF, Hennino A. SLIT prevents the development of eczema in percutaneous allergen-sensitized mice. Journal of Investigative Dermatology. 2012;132(1):244-6.
  108. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, Kundig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. Journal of Allergy and Clinical Immunotherapy. 2012;129(1):128-35.
  109. Alesina R, Milani M, Pecora S. A multicenter, randomized, parallel-group trial assessing compliance, tolerablility, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis. Journal of Allergy Cairo. 2012. Epub retrieved June 19, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22131999
  110. Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell’albani I, Puccinelli P. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy. Journal of Drug Design, Development and Therapy. 2012;6:117-23.
  111. Moussu H, Van Overtvelt L, Horiot S, Tourdot S, Airouche S, Zuercher A, Holvoet S, Prioult G, Nutten S, Mercenier A, Mascaraell L, Moingeon P. Bifidobacterium bifidum NCC 453 promotes tolerance induction in murine models of sublingual immunotherapy. International Archives of Allergy and Immunology. 2011;158(1):35-42.
  112. Panjo GB, Caminiti L, Crisafulli G, Vita D, Valenzise M, De Luca R, Passalacqua G. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. Pediatric Allergy and Immunology. 2011;22(8):803-07.
  113. Tourdot S, Airouche S, Berjont N, Da Silveira A, Mascarell L, Jacquet A, Caplier L, Langelot M, Baron-Bodo V, Moingeon P. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation. Clinical Experimental Allergy. 2011;41(12):1784-92.
  114. Stelmach I, Kaluzinska-Parazyszek I, Jerzynska J, Stelmach P, Stelmach W, Majak P. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children. Allergy. 2011. Epub ahead of print retrieved January 24, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22142341
  115. Barberi S, Villa MP, Panjo GB, La Penna F, Barreto M, Cardelli P, Amodeo R, Tabacco F, Caminiti L, Ciprandi G. Immune response to sublingual immunotherapy in children allergic to mites. Journal of Biological Regulators & Homeostatic Agents. 2011;25(4):627-34.
  116. Theodoropoulos DS, Katzenberger DR, Jones WM, Morris M, Her C, Cullen NA, Morris DL. Allergen-specific sublingual immunotherapy in the treatment of migraines: A prospective study. European Review for Medical and Pharmacological Sciences. 2011;15(10):1117-21.
  117. Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I. A novel approach in allergen-specific immunotherapy: Combination of sublingual and subcutaneous routes. Journal of Allergy and Clinical Immunology. 2011;128(4):808-15.
  118. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ. Sustained 3-year efficacy of pre- and co-seasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2011;128(3):559-66.
  119. Milani M, Pecora S. Clinical relevance of non-grass pollens respiratory allergies in Italy and effects of specific sublingual immunotherapy: The rainbow trial, a multicentre 3-year prospective observational study. European Annals of Allergy and Clinical Immunotherapy. 2011;43(4):111-6.
  120. Kuna P, Samolinski B, Worm M, Pfaar O, Klimek L. Sustained clinical efficacy of sublingual immunotherapy with a high-dose grass pollen extract. European Annals of Allergy and Clinical Immunology. 2011;43(4):117-21.
  121. Gastaminza G, Algorta J, Uriel O, Audicana MT, Fernandez E, Sanz ML, Munoz D. Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patients. Trials. 2011;12:191
  122. Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, et al. Sustained 3 year efficacy in pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2011;128(3):559-66.
  123. Lee J, Choi Y, Kim M, Han D, Rhee C, Lee C, et al. Efficacy of sublingual immunotherapy with house dust mite extract iin polyallergen sensitized patients with allergic rhinitis. Annals of Allergy, Asthma and Immunology. 2011;107(1):79-84.
  124. Panzner P, Petras M, Sykora T, Lesna JK, Liska M. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy. Allergy and Asthma Proceedings. 2011;32(2):142-50.
  125. Panizo C, Cimarra M, Gonzalez-Mancebo W, Vega A, Senent C, Martin S. In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets. Journal of Investigational Allergology and Clincial Immunology. 2010;20(6):454-62.
  126. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. Journal of Allergy and Clinical Immunology. 2011;127(1):72-80.
  127. Yuta A, Ogihara H, Miyamoto Y, Takeuchi K, Okubo K. The enhanced clinical efficacy by treated years and the sustained efficacy after treatment of sublingual immunotherapy for Japanese cedar pollinosis. Arerugi. 2010;9(11):1552-61.
  128. Pozzan M, Milani M. Efficacy of sublingual specific immunotherapy in patients with respiratory allergy to Alternaria alternata:a randomised, assessor-blinded, patient-reported outcome, controlled 3-year trial. Current Medical Research and Opinion. 2010;26(12):2801-6.
  129. Cortellini G, Spadolini I, Patella V, Fabbri E, Santucci A, Severino M, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis:a randomized placeo-controlled trial. Annals of Allergy, Asthma & Immunology. 2010;105(5):382-6.
  130. Yonekura S, Okamoto Y, Sakurai D, Horiguchi S, Hanazawa T, Nakano A. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergology International. 2010;59(4).
  131. Incorvaia C, Rapetti A, Scurati S, Puccinelli P, Capecce M, Frati F. Importance of patient’s education in favoring compliance with sublingual immunotherapy. Allergy. 2010;65(10):1341-2.
  132. Skoner D, Gentile D, Bush R, Fasano M, McLaughlin A, Esch R. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Journal of Allergy and Clinical Immunology. 2010;125(3):660-6.
  133. Durham S, Emminger W, Kapp A, Colombo G, de Monchy J, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Journal of Allergy and Clinical Immunology. 2010;125:131.
  134. Ariano R, Berto P, Incorvaia C, Di Cara G, Boccardo R, LaGrutta S, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in allergic asthma. Annals of Allergy, Asthma and Immunology. 2009;103:254-259.
  135. Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, Decinti M, et al. Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy. Journal of Allergy and Clinical Immunology. 2009;124(2):385.
  136. Reshamwala N, Song S, Yu GP, Swamy R, Berquist W, Nguyen T, et al. Study of Sublingual Immunotherapy in Subjects with Dermatophagoides Farniae and Timothy Grass Allergy. Journal of Allergy and Clinical Immunology. 2008;123(2).
  137. Emminger W, Durham S, Riis B, Maloney J, Nolte H. The efficacy of Single-grass-allergen-immunotherapy-tablet Treatment in Mono- and Multi-sensitized Allergic Rhinitis Patients: Findings from a Post Hoc Analysis. Journal of Allergy and Clinical Immunology. 2008;123(2)
  138. Seidenberg J, Wahn U, Emeryk A, Lheritier-Barrand M, Gall M. Evaluation of a Five Grass-pollen Sublingual Immunotherapy Tablets (SLIT) in a Pediatric Population at Peak Pollen Season and Immunological Outcomes. Journal of Allergy and Clinical Immunology. 2008;123(2).
  139. Bufe A, Henmar H, Gronager P, Durham S. Sublingual Immunotherapy with Fast-Dissolving Grass Tablets Induces Comparable IgF4 Antibody and IgE-blocking Responses in Children and Adults. Journal of Allergy and Clinical Immunology. 2009;123(2).
  140. Marogna M, Spadolini I, Massolo A, Berra D, Zanon ., Chiodini E, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Annals of Allergy, Asthma & Immunology. 2009;102:69-75.
  141. Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. European Annals of Allergy and Clinical Immunology. 2007;39(5):148-156.
  142. Severino M, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind placebo-controlled trial. American Academy of Allergy, Asthma & Immunology. 2008:1-5.
  143. Alvarez-Cuesta E, Berges-Gimeno P, Mancebo EG, Fernandez-Caldas E, Cuesta-Herranz J, Casnovas M. Sublingual immunotherapy with a standardized cat dander extract: Evaluation of efficacy in a double blind placebo controlled study. Allergy: European Journal of Allergy and Clinical Immunology. 2007;62(7):810-817.
  144. Esch R. Sublingual immunotherapy. Current Opinion in Otolaryngology & Head and Neck Surgery 2008;16:260-264.
  145. Esch, R., Bush, R., Peden, D., Lockey, R. Sublingual-oral administration of standardized allergenic extracts:Phase one safety and dosing results. Annals of Allergy, Asthma and Immunology. 2008;100(5):475-481.
  146. Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunni N, et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. International Archives of Allergy & Immunology. 2008;146:76-84.
  147. Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: Results from the SIMAP database study. Current Medical Research and Opinion. 2008;24(1):261-266.
  148. Jacobsen L, Valovirta E. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma. Current Opinion in Allergy & Clinical Immunology. 2007;7(6):556-560.
  149. Nuhoglu Y, Ozumut SS, Ozdemir C, Ozdemir M, Nuhoglu C, Erguven M. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: A retrospective analysis of clinical course over a 3-year follow-up period. Journal of Investigational Allergology and Clinical Immunology. 2007;17(6):375-378.
  150. De Blay F, Barnig C., Kanny G, et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Annals of Allergy, Asthma, and Immunology. 2007;99:453-461.
  151. Penagos M, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2007.
  152. Cadario G. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity:a prospective pilot study. Current Medical Research and Opinion. 2007;23(100):2503-6.
  153. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007;62(8):954-7.
  154. Grier T, et al. Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. Annals of Allergy, Asthma, and Immunology. 2007;99:151-160.
  155. Ozdemir C, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mire-allergic children with asthma. Pediatric Allergy and Immunology. 2007;18:508-515.
  156. Roder E, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. Journal of Allergy and Clinical Immunology. 2007;119(4):892-898.
  157. Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau M, Massabie-Bouchat Y, Aferiat-Derome A, Andre C. Safety and efficacy of juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis:A double-blind, placebo-controlled study. International Archives of Allergy and Immunology. 2007;142:239-246.
  158. Di Rienzo V, Pucci S, D’Alo S, Di Cara G, Incorvania C., Frati F, Romano A. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: A placebo-controlled study. Clinical and Experimental Allergy Reviews. 2006;6:67-70.
  159. Kinaciyan T, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. Journal of Allergy and Clinical Immunology. 2007;119(4):937-943.
  160. Penagos M, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: A meta-analysis of randomized, placebo-controlled, double-blind trials. Annals of Allergy Asthma and Immunology. 2006;97(2):141-8.
  161. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Annals of Allergy, Asthma & Immunology. 2006;97:158-163.
  162. Dahl, R, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 2006;118(2):434-440.
  163. Valovirta E, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61:1177-1183.
  164. Calamita Z. et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006;61:1162-1172.
  165. Bernardini R, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double blind, placebo-controlled study. Current Medical Research and Opinions. 2006;22(8):1515-1522.
  166. Niu C, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma:A multi-center, double-blind, randomized and placebo-controlled study in Taiwan. Respiratory Medicine. 2006:1-10.
  167. Olaguibel J, Alvarez Puebla M. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. Journal of Investigational Allergology and Clinical Immunology. 2005;15(1):9-16.
  168. Di Rienzo V, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clinical and Experimental Allergy. 2005;35(5):560.
  169. Fiocchi A, et al. A prospective study on safety of sublingual immunotherapy in children aged 3 to 6 years. Journal of Allergy and Clinical Immunology. 2005;115(2):S265.
  170. Tesse R, et al. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome. Journal of Allergy and Clinical Immunology. 2005;115(2):S266.
  171. Bahceciler N, et al. Impact of sublingual immunotherapy on specific antibody levels in children allergic to house dust mites. International Archives of Allergy and Immunology. 2005;136(3):287-294.
  172. Wilson D, et al. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60(1):page 4.
  173. Marogna M, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: Clinical efficacy and more. Allergy. 2004;59(11):1205-1210.
  174. Novembre E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. Journal Allergy and Clinical Immunology. 2004;114(4):851-857.
  175. Smith H, et al. Randomized controlled trial of high-dose sublingual immunotherapy to treat allergic rhinitis. Journal Allergy and Clinical Immunology. 2004;114(4):831- 837.
  176. Savi E, et al. A latex-containing hepatitis-B vaccine administered in a severely latex allergic paediatric patient after specific sublingual immunotherapy: A case report. Allergy. 2004;59(9):1014-1015.
  177. Drachenberg K, et al. Sublingual specific immunotherapy for adults and children: A post marketing surveillance study. Journal of Investigational Allergology and Clinical Immunology. 2004;32(2):76-81.
  178. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. American Journal of Clinical Dermatology. 2004;5(5):281-294.
  179. Cistero B, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. Journal of Investigational Allergology and Clinical Immunology. 2004;14(1):17-25.
  180. Khinchi M. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy:A randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59:45-53.
  181. Tonnel A, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004;59:491-197.
  182. Bufe A, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms:A double-blind placebo-controlled study. Allergy. 2004;59(5):498-504.
  183. Pajno G, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: A randomized controlled trial dagger. Allergy. 2004;59(8):883-887.
  184. Pajno, G, et al. Comparisons between injection and sublingual immunotherapy for rhinitis and asthma in allergic children to house dust mite or parietaria pollen. A case controlled study. Journal of Allergy and Clinical Immunology. 2004;113(2):(abs.).
  185. Niu C, et al. Efficacy and safety of sublingual immunotherapy with high dose house dust mite extract in asthmatic children – a multicenter randomized double-blind, and placebo-controlled study. Journal of Investigational Allergology and Clinical Immunology. 2004;113(2):(abs.).
  186. Mauro M., et al. Efficacy and safety of subcutaneous and sublingual immunotherapy in birch pollinosis. Journal of Allergy and Clinical Immunology. 2004;113(2).
  187. Melranci C, Matteoli M. Efficacy of allergoid sublingual immunotherapy in children with asthma and/or allergic rhinoconjunctivitis: Comparison study with drugs. Journal of Allergy and Clinical Immunology. 2004;113(2):(abs.).
  188. Bassi M, et al. High dose sublingual immunotherapy: Economic evaluation from an Italian observational data base study. Journal of Allergy and Clinical Immunology. 2004;113(2):(abs.).
  189. Pajno G. Efficacy of sublingual immunotherapy in asthma and eczema. Chemical Immunology and Allergy. 2003;82:77-88.
  190. Wuthrich B, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. Journal of Investigational Allergology and Clinical Immunology. 2003;13(3):145-148
  191. Andre C, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. International Archives of Allergy and Immunology. 2003;131:111-118.
  192. Ippoliti, F., et al. Immunomodulation during sublingual therapy in allergic children. Pediatric Allergy and Immunology. 2003;14:216-221.
  193. Pajno G, et al. Parietaria pollen sublingual immunotherapy for asthmatic children: Seasonal behavior in methacholine PC20. Journal of Allergy and Clinical Immunology. 2003:(abs).
  194. Mortemousque B, et al. House-dust mite sublingual –swallow immunotherapy in perennial conjunctivitis:A double-blind, placebo-controlled study. Clinical and Experimental Allergy. 2003;33:464-469.
  195. Gonzalez E, et al. Efficacy and safety of a standardized sublingual therapeutic vaccine of cat epithelia extract. Journal of Allergy and Clinical Immunology. 2003: S200(abs).
  196. Cirla A, et al. A pre-seasonal birch/hazel sublingual immunotherapy can improve the outcome of grass pollen injective treatment in bisensitized individuals. A case-referent, two year controlled study. Allergologia et Immunopathologia. 2003;31(1):31-43.
  197. Madonini F, et al. Long-term and preventive effects of sublingual allergen specific immunotherapy:A retrospective, multicentric study. International Journal of Immunopathology and Pharmacology. 2003;16(1):73-79.
  198. Bordignon V, Parmiani S. Variation of the skin end-point in patients treated with sublingual specific immunotherapy. Journal of Investigative Allergology and Clinical Immunology. 2003;13(3):170-176.
  199. Torres Lima M, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: A randomized controlled trial. Clinical and Experimental Allergy. 2002;32:507-514.
  200. Silvestri M, et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity in asthmatic children sensitized to house dust mites following sublingual immunotherapy. Journal of Investigative Allergology and Clinical Immunology. 2002;12(1):6-7 (abs).
  201. Velarde-Domiquez T, et al. Clinical effectiveness and security of sublingual immunotherapy as a treatment for allergy asthma secondary to Dermaphgoides in pediatric population. Revista de Sanidad Militar. 2002;56(1):10-14 (abs).
  202. Criado Molina A1, et al. [Immunotherapy with an oral Alternaria extract in childhood asthma. Clinical safety and efficacy and effects on in vivo and invitro parameters]. Allergologia et Immunopathologia 2002;30(6):319-330.
  203. Olaguibel J, et al. Adherence to and safety of a high dose sublingual immunotherapy regimen with a standardized grass pollen extract. Journal of Allergy and Clinical Immunology. 2002;109(1):S201.
  204. Pajno G, et al. Impact of sublingual immunotherapy on seasonal asthma of allergic children to parietaria pollen treated with inhaled fluticasone propionate. Journal of Allergy and Clinical Immunology. 2002;109(1):S200.
  205. Ariano R, et al. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergologia et Immunopathologia. 2001; 29(6):238-244.
  206. Bahceciler N, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double-blind, placebo-controlled study. Pediatric Pulmonology. 2001;32:49-55.
  207. Caffarelli C, et al. Preseasonal local allergoid immunotherapy to grass pollen in children. Allergy. 2000;55:1142-1147.
  208. Valle C, et al. Effects of sublingual immunotherapy in patients sensitized to Ambrosia. An open controlled study. Allergologia et Immunopathologia. 2000;28(6):311-317.
  209. Mastrandrea F, et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergologia et Immunopathologia. 2000;28(2):54-62.
  210. Pajno G, et al. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind placebo controlled study. Allergy. 2000;55:842-849.
  211. Guez S, et al. House dust mite SLIT in perennial rhinitis: A double blind placebo controlled study. Allergy. 2000;55:369-375.
  212. Pradalier A, et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy. 1999;54:819-828.
  213. Bousquet J., et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double blind, placebo-controlled study. Allergy. 1999;54(3):249-260.
  214. Purello-D’Ambrosio F, et al. Sublingual immunotherapy: A double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy. 1999;54:968-973.
  215. La Rosa M, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology. 1999:425-432.
  216. Passalacqua G, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 1999:964-968.
  217. Di Rienzo V, et al. Grass pollen specific sublingual/swallow immunotherapy in children: Open-controlled comparison among different treatment protocols. Allergologia et Immunopathologia. 1999;27(3):145-151.
  218. Vourdas D, et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy. 1998;53:662-672.
  219. Clavel R, Bousquet J, et al. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of standardized five-grass-pollen extract in rhinitis. Allergy. 1998;53:493-498.
  220. Horak F, et al. Immunotherapy with sublingual birch pollen extract. A short-term double blind placebo study. Journal of Investigative Allergology and Clinical Immunology. 1998;8(3):165-171.
  221. Hordijk G, et al. Sublingual immunotherapy with a standardised grass pollen extract: A double-blind placebo-controlled study. Allergologia et Immunopathologia. 26(5):234-240.
  222. Passalacqua G, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. The Lancet. 1998;351:629-632.
  223. Luwema R, et al. Sublingual immunotherapy with a standardized grass pollen extract (Oralgen); A placebo controlled study. The Journal of Allergy and Clinical Immunology. 1997;99(1):Part 2 (abs 282).
  224. Passalacqua G, et al. Clinical and immunological effects of a long-term sublingual-oral immunotherapy to mite: A double blind study. The Journal of Allergy and Clinical Immunology. 1997;99(1):Part 2 (abs 1630).
  225. Van Deusen M, et al. Efficacy and safety of oral immunotherapy with short ragweed. Annals of Allergy, Asthma & Immunology. 1997;78:573-580.
  226. Gozalo F., et al. Clinical efficacy and tolerance of two year Lolium perenne sublingual immunotherapy Allergologia et Immunopathologia. 1997;25(5):219-227.
  227. Passalacqua G. Sublingual immunotherapy: Accumulated experience. Journal of Investigative Allergology and Clinical Immunology. 1997;7(5):364-366.
  228. Hirsh T, et al. Double blind placebo controlled study of sublingual immunotherapy with house dust mites extracts in children. Pediatric Allergy & Immunology. 1997;8:21-27.
  229. Purello-D’Ambrosio F, et al. Rush sublingual immunotherapy in parietaria allergic patients. Allergologia et Immunopathologia. 1996;21(4):146-151.
  230. Troise C, et al. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: A double-blind study. Journal of Investigational Allergology and Clinical Immunology. 1995;5(1):25-30.
  231. Clavel R, et al. Reduction of corticosteroid therapy by sublingual immunotherapy. Double blind study against placebo of Standardized 5 Grass Pollen Extract in Rhinitis. Allergy. 1995; 50(26):279.
  232. Giovane A, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: Evidence of safety and efficacy in pediatric patients. Clinical and Experimental Allergy. 1994;24:53-59.
  233. Sabbah A, et al. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen. Allergy. 1994;49:309-313.
  234. Casanovas M, et al. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. Journal of Investigational Allergology and Clinical Immunology. 1994;4(6):305-314.
  235. Tari M., et al. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergologia et Immunopathologia 1994;22(5):209-216.
  236. Tari M, et al. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite-A double blind study. Allergologia et Immunopathologia. 1990; 18(5):277-284.
  237. Leng X, et al. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Annals of Allergy, Asthma & Immunology. 1990;64:27-31.
  238. Taudorf E, et al. Oral immunotherapy in birch pollen hay fever. Journal of Allergy and Clinical Immunology. 1987;80(2):153-161.
  239. Van Nierkerk C, De Wet J. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever; A double blind study. Clinical and Experimental Allergy. 1987;17:507-513.
  240. Scadding G., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clinical and Experimental Allergy. 1986;16:483-491.
  241. Morris D. Treatment of respiratory disease with ultra-small doses of antigens. Annals of Allergy, Asthma & Immunology. 1970;28(10):494-500.

3. Comparison Studies of Sublingual and Subcutaneous Antigen Administration

  1. Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cellular & Molecular Immunology. 2016 Apr 11. doi: 10.1038/cmi.2016.14. [Epub ahead of print]
  2. Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. Journal of Allergy and Clinical Immunology. 2016 Oct;138(4):1081-1088. doi: 10.1016/j.jaci.2016.04.061.
  3. Durham SR, Creticos PS, Nelson HS, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cellular and Molecular Immunology. 2016 Apr 11. doi: 10.1038/cmi.2016.14. [Epub ahead of print].
  4. Karakoc-Aydiner E, Eifan AO, Baris S, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: A 3-year prospective randomized controlled trial. Journal of Investigational Allergology and Clinical Immunology. 2015;25(5):334-42. Epub ahead of print retrieved April 26, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/26727762
  5. Luo X, Hong H, Tang J, et al. Increased expression of miR-146a in children with allergic rhinitis after allergen-specific immunotherapy. Allergy, Asthma & Immunology Research. 2016 Mar;8(2):132-140. doi: 10.4168/aair.2016.8.2.132. Epub 2015 Oct 22.
  6. Chester JG, Bremberg MG, Reisacher WR. Patient preferences for route of allergy immunotherapy: A comparison of four delivery methods. International Forum of Allergy & Rhinology. 2016 Feb 2. doi: 10.1002/alr.21707. [Epub ahead of print]
  7. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? Journal of Allergy and Clinical Immunology. 2016 Feb;137(2):339-349.e10. doi: 10.1016/j.jaci.2015.12.1298.
  8. Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy and Asthma Proceedings. 2016 Jan;37(1):50-56. doi: 10.2500/aap.2016.37.3907. [Epub ahead of print]
  9. Leader BA, Rotella M, Stillman L, DelGaudio JM, Patel ZM, Wise SK. Immunotherapy compliance: Comparison of subcutaneous versus sublingual immunotherapy. International Forum of Allergy & Rhinology. 2015 Dec 31. doi: 10.1002/alr.21699. [Epub ahead of print]
  10. Yuta, A, Ogawa Y, Suzuki Y, et al. Clinical efficacy of sublingual immunotherapy for Japanese cedar pollinosis in the first follow-up year. Japanese Journal of Allergology. 2015 Dec;64(10):1323-1333. doi: 10.15036/arerugi.64.1323. [Epub ahead of print]
  11. Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of aeroallergen immunotherapy: Subcutaneous immunotherapy and sublingual immunotherapy. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):71-86. doi: 10.1016/j.iac.2015.08.003.
  12. Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: Comparative efficacy, current and potential indications, and warnings-United States versus Europe. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):13-24. doi: 10.1016/j.iac.2015.08.005.
  13. Miao Q, et al. A comparison of the effects of subcutaneous and sublingual immunotherapy on immunological responses in children with asthma. The Chinese Journal of Contemporary Pediatrics. 2015 Nov;17(11):1210-1216. Epub ahead of print retrieved November 18, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26575880
  14. Schulten V, et al. Distinct modulation of allergic T cell responses by subcutaneous versus sublingual allergen-specific immunotherapy. Clinical & Experimental Allergy. 2015 Oct 5. doi: 10.1111/cea.12653. [Epub ahead of print]
  15. Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen-induced allergic rhinitis – Differences between subcutaneous and sublingual treatment. Basic & Clinical Pharmacology & Toxicology. 2015 Aug;117(2):73-84. doi: 10.1111/bcpt.12416. Epub 2015 Jun 3.
  16. French C, Seiberling K. Comparative costs of subcutaneous and sublingual immunotherapy. Current Opinion in Otolaryngology & Head and Neck Surgery. 2015 Jun;23(3):226-9. doi: 10.1097/MOO.0000000000000159.
  17. Nelson H1, Cartier S2, Allen-Ramey F3, Lawton S4, Calderon MA5. Network meta-analysis show commercialized subcutaneous and sublingual grass products have comparable efficacy. Journal of Allergy and Clinical Immunology. In Practice. 2015 Mar-Apr;3(2):256-266.e3. doi: 10.1016/j.jaip.2014.09.018. Epub 2014 Nov 20.
  18. Tabatabaian F1, Casale TB. Selection of patients for sublingual immunotherapy (SLIT) versus subcutaneous immunotherapy (SCIT). Allergy and Asthma Proceedings. 2015 Mar-Apr;36(2):100-4. doi: 10.2500/aap.2015.36.3830.
  19. Verheggen BG1, Westerhout KY1, Schreder CH2, Augustin M3. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clinical and Translational Allergy. 2015 Jan 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015.
  20. Satya ND, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. Journal of Allergy and Clinical Immunology. DOI:10.1016/j.jaci.2014.11.005
  21. Lierl MB. New developments in the treatment of pediatric allergic rhinitis and conjunctivitis. Pediatric Annals. 2014 Aug;43(8):e192-200. doi:10.3928/00904481-20140723-09.
  22. Chelladurai Y1, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis:current update. Current Opinion Otolaryngology & Head and Neck Surgery. 2014 Jun;22(3):211-5. doi:10. 1097/MOO.0000000000000045.
  23. Hankin CS1, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Current Opinion in Allergy and Clinical Immunology. 2014 Aug;14(4):363-70. doi:10.1097/ACI.0000000000000084.
  24. Larenas Linnemann DE1, S Blaiss M. Selection of patients for sublingual versus subcutaneous immunotherapy. Immunotherapy. 2014 Jul;6(7):871-84. doi:10.2217/imt.14.55.
  25. Dranitsaris G1, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinistis:an indirect analysis of efficacy, safety and cost. Journal of Evaluation in Clinical Practice.2014 Jun;20(3):225-38. doi:10.1111/jep.12112. Epub 2014 Jan 21.
  26. Wood RA, Togias A, Wildfire J, Visness CM, Matsui EC, Gruchalla R, Hershey G, Liu AH, O’Connor GT, Pongracic JA, Zoratti E, Little F, Granada M, Kennedy S, Durham SR, Shamji MH, Busse WW. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. Journal of Allergy and Clinical Immunology. 2014 Mar;133(3):846-852
  27. Paino GB, Caminiti L, Passalacqua G. Changing the route of immunotherapy administration: an 18-year survey in pediatric patients with allergic rhinitis and asthma. Allergy and Asthma Proceedings. 2013 Nov-Dec;34(6):523-526.
  28. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clinical and Transitional Allergy. 2013 Dec 21;3(1):42.
  29. Nelson, H. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? Journal of Allergy and Clinical Immunology: In Practice. 2014 Mar-Apr;2(2):144-149.
  30. Frati F, Dell’Albani I, Incorvaia C. Why are direct comparisons of subcutaneous and sublingual immunotherapy so rare? Journal of Allergy and Clinical Immunology. 2014 Mar;133(3):936.
  31. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2013. Epub ahead of print retrieved May 15, 2013, form http://www.ncbi.nlm.nih.gov/pubmed/23651609
  32. Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. Current Allergy and Asthma Reports. 2013;13(2):178-95.
  33. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. Journal of Allergy and Clinical Immunology. 2012;130(5):1097-1107.
  34. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? Current Opinions on Allergy and Clinical Immunology. 2012;12(6):640-7.
  35. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma:a randomized, placebo-controlled, double-blind, double-dummy study. International Archives of Allergy and Immunology. 2012;157(3):288-98.
  36. Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. International Forum of Allergy and Rhinology. 2012. Epub ahead of print retrieved June 19, 2012, from http://1.usa.gov/11Jopin
  37. Calderon  MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Current Opinions in Allergy and Clinical Immunology. 2012;12(3):249-56.
  38. Saporta D. Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients. Journal of Environmental and Public Health. 2012. Epub retrieved June 19, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22523505
  39. La Rosa M, Lionetti E, Leonardi S, Salpietro A, Bianchi L, Salpietro C, Miraglia Del Giudice M, Ciprandi G, Marseglia GL. Specific immunotherapy in children: The evidence. International Journal of Immunopathology and Pharmacology. 2011;24(Suppl. 4):69-78.
  40. Calderon  MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy. 2011. Epub ahead of print retrieved January 24, 2012 from http://www.ncbi.nlm.nih.gov/pubmed/22150126
  41. Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. Pediatric Pulmonology. 2011;3(6):747-56.
  42. Sieber J, Shah-Hosseini K, Mosages R. Specific immunotherapy for allergic rhinitis to grass and tree pollens in daily medical practice-symptom load with sublingual immunotherapy compared to subcutaneous immunotherapy. Annals of Medicine. 2011;43(6):418-24.
  43. Cochard M, Eigenmann P. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. Journal of Allergy and Clinical Immunology. 2009 Aug;124(2):378-9. doi: 10.1016/j.jaci.2009.04.040. Epub 2009 Jul 9.
  44. Larenas-Linnemann D. Subcutaneous and Sublingual Immunotherapy in Children: Complete Update on controversies, Dosing and Efficacy. Current Allergy and Asthma Reports. 2008;8:465-474.
  45. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs. subcutaneous allergen immunotherapy. Annals of Allergy, Asthma and Immunology. 2008;100(5):482-489.
  46. Townley, R. Is Sublingual Immunotherapy “Ready for Prime Time”? Chest. 2008;133:589-590.
  47. Saporta D, McDaniel A. Efficacy comparison of multiple-antigen subcutaneous injection immunotherapy and multiple-antigen sublingual immunotherapy. ENT – Ear, Nose & Throat Journal. 2007;86(8):493-497.
  48. Mauroa M, Russelloa M, Incorvaiab C, Gazzolaa G, Di Carac G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: A randomized study. European Annals of Allergy and Clinical Immunology. 2007;39:119-122.
  49. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59:45-53.
  50. Mungan D, et al. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma a placebo controlled study. Annals of Allergy, Asthma, and Immunology. 1999; 82:485-490.
  51. Quirino T, et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clinical and Experimental Allergy. 1996;26:1253-1261.
  52. Bernardis P, et al. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. Journal of Investigational Allergology and Clinical Immunology. 1996;6(1):55-62.

4. Mechanisms of Sublingual Immunotherapy

  1. Hüser C, Dieterich P, Singh J, et al. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite allergic patients. 2016 Apr 12. doi: 10.1111/all.12913. [Epub ahead of print]
  2. Meng Q, Liu X, Li P, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. International Forum of Allergy & Rhinology. 2016 Aug;6(8):862-70. doi: 10.1002/alr.21743.
  3. Tanaka Y, Nagashima H, Bando K, et al. Oral CD103-CD11b+ classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes. Mucosal Immunology. 2016 May 11. doi: 10.1038/mi.2016.46. [Epub ahead of print]
  4. Nomura T, Suzuki M, Yokota M, et al. Effect of Japanese cedar-specific sublingual immunotherapy on allergen-specific TH2 cell counts in blood. Annals of Allergy, Asthma & Immunology. 2016 Jul;117(1):72-78. doi: 10.1016/j.anai.2016.04.003.
  5. Hagner S, Rask C, Brimnes J, et al. House Dust Mite-Specific Sublingual Immunotherapy Prevents the Development of Allergic Inflammation in a Mouse Model of Experimental Asthma. International Archives of Allergy and Immunology. 2016 Jun;170(1):22-34. doi: 10.1159/000446155.
  6. Shima K, Koya T, Tsukioka K, et al. Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. Allergology International. 2016 Jul 8. pii: S1323-8930(16)30083-1. doi: 10.1016/j.alit.2016.05.012. [Epub ahead of print]
  7. Jerzynska J, Stelmach W, Balcerak J, et al. Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy. Allergy & Asthma Proceedings. 2016 Jul;37(4):324-34. doi: 10.2500/aap.2016.37.3958.
  8. Larenas Linnemann DE, Singh J, Rosario N, et al. Similar biological activity in skin prick test for Oralair® (8200 BAU) and Grazax® (6200 BAU) reinforces effective SLIT dosing level. 2016 Aug 3. doi: 10.1111/all.12998. [Epub ahead of print]
  9. Hüser C, Dieterich P, Singh J, et al. A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite allergic patients. Allergy. 2016 Apr 12. doi: 10.1111/all.12913. [Epub ahead of print]
  10. Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cellular & Molecular Immunology. 2016 Apr 11. doi: 10.1038/cmi.2016.14. [Epub ahead of print]
  11. Würtzen PA, Gupta S, Brand S, Andersen PS. Grass pollen immunotherapy: Where are we now. Immunotherapy. 2016 Apr;8(4):399-411. doi: 10.2217/imt.16.1. [Epub ahead of print]
  12. Meng Q, Liu X, Li P, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. International Forum of Allergy & Rhinology. 2016 Mar 25. doi: 10.1002/alr.21743. [Epub ahead of print]
  13. Luo X, Hong H, Tang J, et al. Increased expression of miR-146a in children with allergic rhinitis after allergen-specific immunotherapy. Allergy, Asthma & Immunology Research. 2016 Mar;8(2):132-140. doi: 10.4168/aair.2016.8.2.132. Epub 2015 Oct 22.
  14. Chester JG, Bremberg MG, Reisacher WR. Patient preferences for route of allergy immunotherapy: A comparison of four delivery methods. International Forum of Allergy & Rhinology. 2016 Feb 2. doi: 10.1002/alr.21707. [Epub ahead of print]
  15. Pishdadian A, Varasteh A, Gholamin M, et al. Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy. Iranian Journal of Basic Medical Sciences. 2016 Jan;19(1):64-71. Epub ahead of print retrieved April 21, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/27096066
  16. Creticos PS. Allergen immunotherapy: Vaccine modification. Immunology And Allergy Clinics of North America. 2016 Feb;36(1):103-24. doi: 10.1016/j.iac.2015.08.010.
  17. Ozdemir C, Kucuksezer UC, Akdis M, Akdis CA. Mechanisms of aeroallergen immunotherapy: Subcutaneous immunotherapy and sublingual immunotherapy. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):71-86. doi: 10.1016/j.iac.2015.08.003.
  18. Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: Comparative efficacy, current and potential indications, and warnings-United States versus Europe. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):13-24. doi: 10.1016/j.iac.2015.08.005.
  19. Salari F, Varasteh AR, Vahedi F, Hashemi M, Sankian M. Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice. International Immunopharmacology. 2015 Dec;29(2):672-8. doi: 10.1016/j.intimp.2015.09.011. Epub 2015 Sep 26.
  20. Li H, Xu E, He M. Cytokine Responses to specific immunotherapy in house dust mite-induced allergic rhinitis patients. Inflammation. 2015 Dec;38(6):2216-23. doi: 10.1007/s10753-015-0204-3.
  21. Gorelik M & Frischmeyer-Guerrerio PA. Innate and adaptive dendritic cell responses to immunotherapy. Current Opinion in Allergy & Clinical Immunology. 2015 Dec; 15(60): 575-80. doi: 10.1097/ACI.0000000000000213.
  22. Larenas-Linnemann, D. Allergen immunotherapy: an update on protocols of administration. Current Opinion in Allergy and Clinical Immunology. 2015 Dec;15(6):556-567. doi:10.1097/ACI.0000000000000220.
  23. Mauro M, Boni E, Makri E, Incorvaia C. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology. 2015 Nov 13:1-7. doi:10.1517/17425255.2015.1113255 [Epub ahead of print]
  24. Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2015 Oct 29. doi: 10.1016/j.jaci.2015.09.015. [Epub ahead of print]
  25. Schulten V, et al. Distinct modulation of allergic T cell responses by subcutaneous versus sublingual allergen-specific immunotherapy. Clinical & Experimental Allergy. 2015 Oct 5. doi: 10.1111/cea.12653. [Epub ahead of print]
  26. Sakashita M, et al. Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a. Cytokine. 2015 Sep;75(1):181-5. doi: 10.1016/j.cyto.2015.03.019. Epub 2015 Apr 28.
  27. Vacher G1, Sublet E1, Gurny R1, Borchard G2. Establishment and first characterization of a sublingual epithelial and immune cell co-culture model. Allergy and Asthma Proceedings. 2015 Mar-Apr;36(2):100-4. doi: 10.2500/aap.2015.36.3830.
  28. Nagai Y1, et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice. Clinical and Experimental Allergy. 2015 Mar;45(3):677-86. doi: 10.1111/cea.12329.
  29. Kim SH1, Mun SJ, Han DH, Kim JW, Kim DY, Rhee CS. Three-year follow-up results of sublingual immunotherapy in patients with allergic rhinitis sensitized to house dust mites. Allergy, Asthma & Immunology Research. 2015 Mar;7(2):118-23. doi: 10.4168/aair.2015.7.2.118. Epub 2014 Oct 30.
  30. Hanci D1, Sahin E, Muluk NB, Cingi C. Immunotherapy in all aspects. European Archives of Oto-rhino-laryngology. 2015 Feb 12. [Epub ahead of print
  31. Allam JP1, Novak N. Immunological mechanisms of sublingual immunotherapy. Current Opinion in Allergy and Clinical Immunology. 2014 Dec;14(6):564-9. doi: 10.1097/ACI.0000000000000118. Jay DC1, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Current Allergy and Asthma Reports. 2014 Nov;14(11):473. doi: 10.1007/s11882-014-0473-1.
  32. Frischmeyer-Guerrerio PA1, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy. Clinical Immunology. 2014 Nov;155(1):47-59. doi: 10.1016/j.clim.2014.08.006. Epub 2014 Aug 27.
  33. Nestor CE1, et al. Sublingual immunotherapy alters expressions of IL-4 and its soluble and membrane-bound receptors. Allergy. 2014 Nov;69(11):1564-6. doi: 10.1111/all.12505. Epub 2014 Sep 13.
  34. Rael E1, Lockey RF2. Optimal duration of allergen immunotherapy. Journal of Clinical Immunology. 2014 Nov;134(5):1218-9.e2. doi: 10.1016/j.jaci.2014.08.046. Epub 2014 Nov 5.
  35. Allam JP1, Novak N. Immunological mechanisms of sublingual immunotherapy. Current Opinion in Allergy and Clinical Immunology.2014 Sep 17. [Epub ahead of print]
  36. Nestor CE1, et al. Sublingual immunotherapy alters expression of IL-4 and its soluble and membrane-bound receptors. Allergy. 2014 Nov;69(11):1564-6. doi:10.1111/all. 12505. Epub 2014 Sep 13.
  37. Toskala E. Immunology. International Forum of Allergy & Rhinology. 2014 Sep;4 Suppl 2:S21-7. doi:10.1002/air.21380.
  38. Frischmeyer-Guerrerio PA1, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy. Clinical Immunology. Aug 27;155(1):47-59. doi:10.1016/j.clim.2014.08.006. [Epub ahead of print]
  39. Cuppari C1, et al. Allergen immunotherapy, routes of administration and cytokine networks:an update. Immunotherapy. 2014 June;6(6):775-86. doi:10.2217/imt.14.47.
  40. Nagai Y1, et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen presenting cells in mice. Clinical & Experimental Allergy. 2014 Apr 28. Doi:10.1111/cea.12329. [Epub ahead of print]
  41. Tian M, Wang Y, Lu Y, Jiang YH, Zhao DY. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4(+) CD25(+) regulatory T cells in peripheral blood of children with allergic asthma. International Forum of Allergy & Rhinology. 2014 May;4(5):371-375.
  42. Shim BS, Choi Y, Cheon IS, Song MK. Sublingual delivery of vaccines for the induction of mucosal immunity. Immune Network. 2013 Jun;13(3):81-85.
  43. Compalati E, Braido F, Walter Canonica G. Sublingual immunotherapy: recent advances. Allergology International. 2013 Dec;62(4):415-523.
  44. Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. Allergy and Asthma Proceedings. 2014 Jan-Feb;35(1):34-42.
  45. Ciepiela O, Zawadzka-Krajewska A, Kotuła I, van Overveld F, Kulus M, Demkow U. Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation. Pediatric Allergy, Immunology, and Pulmonology. 2014 Mar 1;27(1):17-23.
  46. Casale TB, Stokes JR. Immunotherapy: what lies beyond. Annals of Allergy, Asthma & Immunology. 2014 Mar;133(3):612-619.
  47. Steinke JW, Lawrence MG. T-cell biology in immunotherapy. Annals of Allergy, Asthma & Immunology. 2014 Mar;112(3):195-199.
  48. Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, de Frutos C, Blanco C, Carrera AC, Barber D, Varona R. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. The Journal of Allergy and Clinical Immunology. 2014 Jan;133(1):133-138.
  49. Ciepiela O, Zawadzka-Krajewska A, Kotula I, Pyrzak B, Demkow U. Influence of sublingual immunotherapy on the expression of Mac-1 integrin in neutrophils from asthmatic children. Advances in Experimental Medicine and Biology. 2013;756:73-80.
  50. Rolland JM, Prickett S, Gardner LM, O’Hehir RE. T cell targeted strategies for improved efficacy and safety of specific immunotherapy for allergic disease. Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23597085
  51. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, Hwang PH, Hoyte EG, Garcia MA, Nadeau KC. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2012;130(1):215-24.
  52. Guida G, Boita M, Scirelli T, Bommarito L, Heffler E, Badiu I, Bellone G, Mietta S, Mistrello G, Rolla G. Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy. Allergy and Asthma Proceedings. 2012;33(5):411-5.
  53. Baron-Bodo V, Batard T, Nguyen H, Frereux M, Horiot S, Harwanegg C, Bergmann KC, de Beaumont O, Moingeon P. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clinical and Experimental Allergy. 2012;42(10):1510-8.
  54. Di Gioacchino M, Cavallucci E, Ballone E, Cervone M, Di Rocco P, Piunti E, Filardo GS, Turi MC, Mangifesta R, Quecchia C, Mistrello G, Braga M, Petrarca C. Dose-dependent clinical and immunological efficacy of sublingual immunotherapy with mite monomeric allergoid. International Journal of Immunopathology and Pharmacology. 2012;25(3):671-9.
  55. Yamada T, Tongu M, Goda K, Aoi N, Morikura I, Fuchiwaki T, Kawauchi H. Sublingual immunotherapy induces regulatory function of IL-10-Expressing CD4(+)CD25(+)Foxp3(+) T cells of cervical lymph nodes in murine allergic rhinitis model. Journal of Allergy. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23118775
  56. Bonvalet M, Moussu H, Wambre E, Ricarte C, Horiot S, Rimaniol AC, Kwok WW, Horak F, de Beaumont O, Baron-Bodo V, Moingeon P. Allergen-specific CD4(+) T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy. Clinical and Experimental Allergy. 2012;42(12):1745-55.
  57. Marcucci F. Sensi L, Incorvaia C, Dell’albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. Clinical Molecular Allergy. 2012. Epub ahead of print retrieved June 19, 2012 from http://www.ncbi.nlm.nih.gov/pubmed/22694773
  58. Zimmer A, Bouley J, Le Mignon M, Pliquet E, Horiot S, Turfkruyer M, Baron-Bodo V, Horak F, Nony E, Louise A, Moussu H, Mascarell L, Moingeon P. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2012;129(4):1020-30.
  59. Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, Hwang PH, Hoyte EG, Garcia MA, Nadeau KC. Epigenetic modifications and improved regulatory T-cell function in subjects dual sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2012. Epub ahead of print retrieved June 19, 2012 from http://1.usa.gov/1A7THet
  60. Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology. 2012;12(1):1-6.
  61. Allam JP, Novak N. Local immunotherapy mechanisms of sublingual immunotherapy. Current Opinion in Allergy and Clinical Immunology. 2011;11(6):571-8.
  62. Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: Mechanisms and applications. Clinical and Developmental Immunology. 2011. Epub ahead of print retrieved January 24, 2011 from http://www.ncbi.nlm.nih.gov/pubmed/22110534
  63. Szczawinska-Poplonyk A. Development of mucosal immunity in children: A rationale forsublingual immunotherapy. Journal of Allergy. 2011. Epub ahead of print retrieved January 24, 2012 from http://www.ncbi.nlm.nih.gov/pubmed/22121386
  64. van Overtvelt L, Baron-Bodo V, Horiot S, Moussu H, Ricarte C, Horak F, et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy. [Published online ahead of print August 29, 2011]. 2011. http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1398-9995/earlyview. Accessed September 16, 2011
  65. Shamji, MH, Durham, SR. Mechanisms of immunotherapy to aeroallergens. Clinical and Experimental Allergy. 2011;41(9):1235-46.
  66. Novak N, Allam P. Mucosal dendritic cells in allergy and immunotherapy. Allergy. 2011;95:22-4.
  67. Wang Z, Li W, Chen H, Zhang W. Effect of sublingual immunotherapy on level of cytokines in PBMCs of patients with allergic asthma. Journal of Huazhong University of Science and Technology Medical Science. June 2011;31(3):376-8.
  68. Ciprandi G, De Amici M, Marseglia GL. Serum Il-9 levels and sublingual immunotherapy: preliminary report. Journal of Biological Regulators and Homeostatic Agents. 2011;25(2):295-7.
  69. Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. Immunology and Allergy Clinics of North America. 2011;31(2):191-209.
  70. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy. 2011;66(6):733-9.
  71. Angelini F, Pacciani V, Corrente S, Silenzi R, Di Pede A, Polito A, et al. Dendritic cells modification during sublingual immunotherapy in children with allergic symptoms to house dust mites. World Journal of Pediatrics. 2011;7(1):24-30.
  72. Piconi S, Trabattoni D, Rainone V, Borgonovo L, Passerini S, Rizzardini G, et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. Journal of Immunology. 2010;185(12):7723-30.
  73. Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells:there is clinical relevance. Clinical and Experimental Allergy. 2010;40(6):922-32.
  74. Dahl R, Kapp A, Colombo G, de Monchy J, Rak S, Emminger W, et.al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Journal of Allergy and Clinical Immunology. 2008;121(2):512-518.
  75. Incorvaia C, Frati F, Puccinelli P, Marcucci F, Di Cara G, Sensi L, et al. Effects of sublingual immunotherapy on allergic inflammation. Inflammation & Allergy Drug Targets. 2008; 7:167-172.
  76. Burastero ., et al. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Annals of Allergy, Asthma & Immunology. 2008;100:343-349.
  77. Bohle B, Kinaciyan T, Gersymayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. Journal of Allergy and Clinical Immunology. 2007;120:707-713.
  78. Ciprandi G, Cirillo I, Tosca M, Marseglia G, Fenoglio D. Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: Preliminary results. Allergy and Asthma Proceedings. 2007;28(5):574-577.
  79. Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual Immunotherapy in sensitized Mice. Annals of Allergy, Asthma & Immunology. 2007 Apr;98(4):3266-72.
  80. Akdis M, Akdis C. Mechanisms of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology. 2007;119(4):780-791.
  81. Bahceciler N, et al. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Current Medical Chemistry. 2007;14:265-269.
  82. Ciprandi G, et al. Sublingual immunotherapy: An update on immunologica and functional effects. Allergy and Asthma Proceedings. 2007;28(1):40-43.
  83. Frati F, et al. Mucosal immunization application to allergic disease: Sublingual immunotherapy. Allergy and Asthma Proceedings. 2007;28(1):35-39.
  84. Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine. 2007;25(5):957-964.
  85. Savolainen J, et al. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy. 2006;61:1184-1190.
  86. Sun J, et al. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scandinavian Journal of Immunology. 2006;64:251-259.
  87. Akdis C, et al. Immunological mechanisms of sublingual immunotherapy. Allergy. 2006;61:11.
  88. Ciprandi G, et al. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: Preliminary reports. International Immunopharmacology. 2006;6:1370-1373.
  89. Jutel M, et al. Mechanisms of allergen specific immunotherapy – T-cell tolerance and more. Allergy. 2006;61:796-807.
  90. Malling H, et al. Safety and immunological changes during sublingual immunotherapy with standarized quality grass allergen tablets. Journal of Investigative Allergology and Clinical Immunology. 2006;16(3):162-168.
  91. Cosmi L, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-y-and interleukin-10-production. Clinical and Experimental Allergy. 2006;36:261-272.
  92. Ciprandi G, et al. Allergen-specific immunotherapy: An update on immunological mechanisms of action. Monaldi Archives for Chest Disease. 2006;65(1):34-37.
  93. Ciprandi G, et al. Sublingual immunotherapy and regulatory T-cells. Allergy. 2006;61:511-513.
  94. Dehlink E, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clinical and Experimental Allergy. 2006;36:32-39.
  95. Moingeon, P., et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006;61:151-165.
  96. Omata N, et al. Ovalbumin-specific IgE modulates ovalbumin-specific T-cell response after repetitive oral antigen administration. Journal of Allergy and Clinical Immunology. 2005 Apr;116(4):822-7.
  97. Ciprandi G., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites:A preliminary report. Annals of Allergy, Asthma & Immunology. 2005;95(1):38-44.
  98. Lambrecht B. Dendritic cells in the pathogenesis of asthma. Clinical and Experimental Allergy. 004;4:123-128.
  99. Jan de Heer H, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. Journal of Experimental Medicine. 2004;200(1):89-98.
  100. Arikan C, et al. BCG-induced IL-12 did not improve parameters in asthmatic children treated w/sublingual immunotherapy. Clinical and Experimental Allergy. 2004;34:398-405.
  101. Reich M, et al. Nonspecific plasma proteins during sublingual immunotherapy. Local Immunotherapy in Allergy. Chemical Immunology. 2003;82:99-108.
  102. Bagnasco M, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clinical and Experimental Allergy. 2001;31:54-60.
  103. Marcucci F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT):Safety and immunologic implications. Allergy. 2001;56:1091-1095.
  104. Markert, U.R. Preliminary analysis of clinical parameters, plasma proteins and T cell functions of allergic patients after up to 3 years sublingual immunotherapy- Abstract presented October 2000 IACAI conference.
  105. Fanta C, et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. International Archives of Allergy and Immunology. 1999;120:218-224.
  106. Yuksel H, et al. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. Journal of Investigative Allergology and Clinical Immunology. 1999;9(5):305-313.
  107. Bagnasco M, et al. Absorption and distribution kinetics of the major Parietaria allergen administered by noninjectable routes to healthy human beings. Journal of Allergy and Clinical Immunology. 1997Jul;100:13-18.
  108. Giannarini L. Decrease of allergen-specific T cell response induced by local nasal immunotherapy. Clinical and Experimental Allergy. 1998;28:547-551.

5. Safety, Quality-of-Life and Adherence Related Studies

  1. Tam HH, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. 2016 Sep;71(9):1345-56. doi: 10.1111/all.12932. Epub 2016 Jun 22.
  2. Moral A, Moreno V, Girón F, et al. Adverse reactions and tolerability of high-dose sublingual allergen immunotherapy. Journal of Asthma and Allergy. 2016 Jun 29;9:129-33. doi: 10.2147/JAA.S107830.
  3. Horn A, Zeuner H, Wolf H, et al. Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study. Clinical Drug Investigation. 2016 Jun;36(6):453-62. doi: 10.1007/s40261-016-0388-9.
  4. Virchow JC, Backer V, Kuna P, et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016 Apr 26;315(16):1715-25. doi: 10.1001/jama.2016.3964.
  5. Roux M, Devillier P, Yang WH, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. Journal of Allergy and Clinical Immunology. 2016 Aug;138(2):451-458. doi: 10.1016/j.jaci.2016.03.039.
  6. Maina E, Cox E. A double blind, randomized, placebo controlled trial of the efficacy, quality of life and safety of food allergen-specific sublingual immunotherapy in client owned dogs with adverse food reactions: a small pilot study. Veterinary Dermatology. 2016 Oct;27(5):361-e91. doi: 10.1111/vde.12358.
  7. Lemberg ML, Eberle P, Shah-Hosseini K. Importance of Quality of Life for Adherence to Sublingual Immunotherapy. BioMed Research International. 2016:5186765. doi: 10.1155/2016/5186765.
  8. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2016 Aug 10. pii: S0091-6749(16)30783-7. doi: 10.1016/j.jaci.2016.06.044. [Epub ahead of print]
  9. Rodríguez Del Río P, Vidal C, Just J, et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a paediatric assessment. Pediatric Allergy and Immunology. 2016 Sep 17. doi: 10.1111/pai.12660. [Epub ahead of print]
  10. Scholz FM, Burrows AK, Muse R. First report of angio-oedema subsequent to the administration of allergen specific sublingual immunotherapy for the management of equine hypersensitivity dermatitis. Veterinary Dermatology. 2016 Oct;27(5):439-e115. doi: 10.1111/vde.12349.
  11. Malet A, Azpeitia A, Gutiérrez D, et al. Comprehensive Study of Patients’ Compliance with Sublingual Immunotherapy in House Dust Mite Perennial Allergic Rhinitis. Advances in Therapy. 2016 Jul;33(7):1199-214. doi: 10.1007/s12325-016-0347-0.
  12. Bene J, Ley D, Roboubi R, Gottrand F, Gautier S. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy. Annals of Allergy, Asthma & Immunology. 2016 Apr 5. pii: S1081-1206(16)30055-2. doi: 10.1016/j.anai.2016.03.017. [Epub ahead of print]
  13. Chirumbolo S. Commentary: Sublingual allergen immunotherapy in HIV-positive patients. Frontiers in Immunology. 2016 Mar 31;7:132. doi: 10.3389/fimmu.2016.00132. eCollection 2016.
  14. Horn A, Zeuner H, Wolf H, et al. Health-related quality of life during routine treatment with the SQ-standardised grass allergy immunotherapy tablet: A non-interventional observational study. Clinical Drug Investigation. 2016 Mar 15. doi: 10.1007/s40261-016-0388-9. [Epub ahead of print]
  15. Wang C, Wang K, Liu S, Qin X, Chen K, Zhang T. Decreased level of osteopontin in children with allergic rhinitis during sublingual immunotherapy. International Journal of Pediatric Otorhinolaryngology. 2016 Feb;81:15-20. doi: 10.1016/j.ijporl.2015.12.001. Epub 2015 Dec 13.
  16. Incorvaia C, Mauro M, Leo G, Ridolo E. Adherence to sublingual immunotherapy. Current Allergy and Asthma Reports. 2016 Jan;16(2):12. doi: 10.1007/s11882-015-0586-1. [Epub ahead of print]
  17. Henmar H, Frisenette SM, Grosch K, et al. Fractionation of source materials leads to a high reproducibility of the SQ house dust mite SLIT-tablets. International Archives of Allergy and Immunology. 2016;169(1):23-32. doi: 10.1159/000444016. Epub 2016 Mar 9.
  18. Leader BA, Rotella M, Stillman L, DelGaudio JM, Patel ZM, Wise SK. Immunotherapy compliance: Comparison of subcutaneous versus sublingual immunotherapy. International Forum of Allergy & Rhinology. 2015 Dec 31. doi: 10.1002/alr.21699. [Epub ahead of print]
  19. Yuta, A, Ogawa Y, Suzuki Y, et al. Clinical efficacy of sublingual immunotherapy for Japanese cedar pollinosis in the first follow-up year. Japanese Journal of Allergology. 2015 Dec;64(10):1323-1333. doi: 10.15036/arerugi.64.1323. [Epub ahead of print]
  20. Sahadevan A, Cusack R, Lane SJ. Safety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthma. Irish Medical Journal. 2015 Nov-Dec;108(10):304-307. Epub ahead of print retrieved April 22, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/26817287
  21. Oykhman P, Kim HL, Ellis AK. Allergen immunotherapy in pregnancy. Allergy, Asthma & Clinical Immunology. 2015 Nov 10;11:31. doi: 10.1186/s13223-015-0096-7. eCollection 2015.
  22. Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen-induced allergic rhinitis – Differences between subcutaneous and sublingual treatment. Basic & Clinical Pharmacology & Toxicology. 2015 Aug;117(2):73-84. doi: 10.1111/bcpt.12416. Epub 2015 Jun 3.
  23. Iemoli E, et al. Sublingual allergen immunotherapy in HIV positive patients. Allergy. 2015 Jul 30. doi: 10.1111/all.12713. [Epub ahead of print]
  24. Landi M, Meglio P, Praitano E, Lombardi C, Passalacgua G, Canonica GW. The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clinical and Molecular Allergy. 2015 Jul 24;13(1):15. doi: 10.1186/s12948-015-0021-0. eCollection 2015.
  25. Makatsori M, et al. Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. Clinical Translational Allergy. 2015 Apr 27;5:17. doi: 10.1186/s13601-015-0060-0. eCollection 2015.
  26. Bender BG. Motivating patient adherence to allergic rhinitis treatments. Current Allergy and Asthma Reports. 2015 Mar;15(3):10. doi: 10.1007/s11882-014-0507-8.
  27. Sandrini A, Rolland JM, O’Hehir RE. Current developments for improving efficacy of allergy vaccines. Expert Review of Vaccines. 2015;14(8):1073-87. doi: 10.1586/14760584.2015.1050385. Epub 2015 May 26.
  28. Okamoto Y, et al. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. International Archives of Allergy and Immunology. 2015;166(3):177-88. doi: 10.1159/000381059. Epub 2015 Apr 18.
  29. Katotomichelakis M1, et al. Predictors of quality of life improvement in allergic rhinitis patients after sublingual immunotherapy. Annals of Otology, Rhinology and Laryngology. 2015 Jun;124(6):430-6. doi: 10.1177/0003489414565001. Epub 2014 Dec 23.
  30. Occasi F1, De Castro G, Zicari AM, Indinnimeo L, Tancredi G, Duse M. Sublingual immunotherapy in children and its potential beneficial collateral effect on respiratory tract infections. Current Medical Research and Opinion. 2015 May;31(5):939-41. doi: 10.1185/03007995.2015.1027182. Epub 2015 Mar 31.
  31. Burks AW1, et al. Sublingual immunotherapy for peanut allergy: Long-term follow-up of randomized multicenter trial. Journal of Allergy and Clinical Immunology. 2015 May;135(5):1240-1248.e3. doi: 10.1016/j.jaci.2014.12.1917. Epub 2015 Feb 3.
  32. Özdemir Ö. The local and system reactions due to sublingual immunotherapy: is anaphylaxis associated with therapy? (Comment) Iranian Journal of Allergy, Asthma and Immunology. 2015 Apr;14(2):228-230.
  33. Mitobe Y1, Yokomoto Y, Ohashi-Doi K. Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy. Regulatory Toxicology and Pharmacology. 2015 Apr;71(3):529-40. doi: 10.1016/j.yrtph.2015.02.009. Epub 2015 Feb 17.
  34. Hsiao KC1, Smart J. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. Pediatric Allergy and Immunology. 2015 Feb;26(1):92. doi: 10.1111/pai.12329.
  35. Albin S1, Nowak-Wegrzyn A2. Potential treatments for food allergy. Immunology and Allergy Clinics of North America. 2015 Feb;35(1):77-100. doi: 10.1016/j.iac.2014.09.011. Epub 2014 Nov 21.
  36. McGowan EC1, Wood RA. Sublingual (SLIT) versus oral immunotherapy (OIT) for food allergy. Current Allergy and Asthma Reports. 2014 Dec;14(12):486. doi: 10.1007/s11882-014-0486-9.
  37. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Annals of Allergy, Asthma & Immunology. 2014 Dec;113(6):624-9. doi: 10.1016/j.anai.2014.08.004. Epub 2014 Sep 10.
  38. Le UH1, Burks AW1. Oral and sublingual immunotherapy for food allergy. The World Allergy Organization Journal. 2014 Dec 8;7(1):35. doi: 10.1186/1939-4551-7-35. eCollection 2014.
  39. Hsieh FH. Oral food immunotherapy and iatrogenic eosinophilic esophagitis: an acceptable level of risk? Annals of Allergy, Asthma & Immunology. 2014 Dec;113(6):581-2. doi: 10.1016/j.anai.2014.09.008. Epub 2014 Oct 7.
  40. Szepfalusi Z1, et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and protolerogenic effects. Pediatric Allergy and Immunology. 2014 Dec;25(8):788-95. doi: 10.1111/pai.12310.
  41. Romantsik O1, Bruschettini M, Tosca MA, Zappettini S, Della Casa Alberighi O, Calevo MG. Oral and sublingual immunotherapy for egg allergy. The Cochrane Database of Systematic Reviews. 2014 Nov 18;11:CD010638. doi: 10.1002/14651858.CD010638.pub2
  42. Vazquez-Ortiz M1, Alvaro M, Piquer M, Giner MT, Dominguez O, Lozano J, Jimenez-Feijoo R, Cambra FJ, Plaza AM. Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers. Annals of Allergy, Asthma & Immunology. 2014 Oct;113(4):482-4. doi: 10.1016/j.anai.2014.07.010. Epub 2014 Aug 19.
  43. Li P1, Li Q, Huang Z, Chen W., Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. International Forum of Allergy & Rhinology. 2014 Oct;4(10):796-801. doi:10.1002/air.21397. Epub 2014 Aug 21.
  44. Makatsori M1, Calderon  MA. Anaphylaxis: still a ghost behind allergen immunotherapy. Current Opinion Allergy & Clinical Immunology. 2014 Aug;14(4):316-22. Doi:10.1097/ACU.0000000000000075.
  45. Calderon  MA, et al. An EAACI “European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)”: the methodology. Clinical and Translational Allergy. 2014 Jul 21;4:22. Doi:10.1186/2045-7022. eCollection 2014. http://ww.ctajournal.com/content/4/1/22
  46. Sanchez J. Adherence to allergen immunotherapy improves when patients choose the route of administration: Subcutaneous or sublingual. Allergologia et Immunopathologia. 2014 Sep 5. pii:S0301-0546(14)00128-1. doi:10.1016/j.aller.2014.04.011.[Epub ahead of print]
  47. Goh A. et al. Gum pigmentation: an unusual adverse effect of sublingual immunotherapy. Asia Pacific Allergy. 2014 Jul;4(3):177-9. doi:10.5415/apallergy.2014.4.2.177. Epub 2014 Jul 29.
  48. Nolte H1, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Annals of Allergy, Asthma & Immunology. 2014 Jul;113(1):93-100.e3. doi:10.1016/j.anai.2014.04.018. Epub 2014 May 14.
  49. Frati F1, et al. Safety of sublingual immunotherapy in children. Expert Opinion on Drug Safety. 2014 Jul;13(7):947-53. Doi:10.1517/14740338.2014.918949. Epub 2014 May 12.
  50. Antico A. Long-Term-Adherence to Sublingual Therapy: Literature Review and Suggestions for Management Strategies Based On Patients’ Needs and Preferences. Clinical & Experimental Allergy. 2014 Jun 28. doi:10.1111/cea.12362. [Epub ahead of print]
  51. Bergmann KC, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Journal of Allergy & Clinical Immunology. 2014 Jun;133(6):1608-14.e6. doi:10.1016/j.jaci.2014.11.012. Epub 2013 Dec31.
  52. Balaji R, Parasuramalu BG, Chandregowda BV, Gangaboraiah. Safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis. Allergologia et Immunopathologia. 2014 May-Jun;42(3):2016-23. Doi:10.1016/j.aller.2012.12.005. Epub 2013 Mar 5.
  53. Makatsori M1, et al. Dropouts in sublingual allergen immunotherapy trials – systematic review. Allergy. 2014 May;69(5):571-80. Doi:10.1111/all.12385. Epub 2014 Mar 27
  54. Scalla G, Ciccarelli A, Calabró C. Adverse reaction to sublingual Parietaria vaccine following an ultra-rush induction. European Annals of Allergy and Clinical Immunology. 2014 May;46(3):116-8.
  55. Klimek L, et al. A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clinical and Translational Allergy. 2014, 4:23. http://www.ctajournal.com/content/4/1/23
  56. Laury AM, Schlosser RJ, Wise SK. Sublingual immunotherapy and quality of life. Current Opinion in Otolaryngology & Head and Neck Surgery. 2013 Jun;21(3):252-255.
  57. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? Expert Review of Clinical Immunology. 2013 Oct;9(10):937-947.
  58. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Current Opinion in Allergy and Clinical Immunology. 2013 Dec;13(6):656-662
  59. Ravi A, Rank MA. Reducing and managing systemic reactions to immunotherapy. Current Opinion in Allergy and Clinical Immunology. 2013 Dec;13(6):651-655.
  60. Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243:a large randomized controlled trial. Annals of Allergy, Asthma & Immunology. 2014 Feb;112(2):146-153.
  61. Shao J, Cui YX, Zheng YF, Peng HF, Zheng ZL, Chen JY, Li Q, Cao LF. Efficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis. American Journal of Rhinology & Allergy. 2014 Mar;28(2):131-139.
  62. Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2013 Aug;132(2):353-560.
  63. Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2014 March – April;2(2):152-155.
  64. Makatsori M, Scadding GW, Lombardo C, Bisoffi G, Ridolo E, Durham SR, Senna G. Dropouts in sublingual allergen immunotherapy trials – a systematic review. Allergy. 2014 69 571-580.
  65. Savi E, Peveri S, Senna G, Passalacqua G. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy. 2013 Sep;68(9):1193-5.
  66. Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Soulie S, Zeldin RK. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clinical Experimental Allergy. 2013;43(5):568-77.
  67. Vovlolis V, Kalogiros L, Mitsias D, Sifnaios E. Severe repeated anaphylactic reactions to sublingual immunotherapy. Allergologia et Immunopathologia. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23253689
  68. Mailhol C, Didier A. Allergen-specific immunotherapy in the treatment of pollen allergy. Revue des Maladies Respiratoires. 2013;30(2):142-51.
  69. Mun SJ, Shin JM, Han DH, Kim JW, Kim DY, Lee CH, Min YG, Rhee CS. Efficacy and safety of a once-daily sublingual immunotherapy without escalation regimen in house dust mite-induced allergic rhinitis. International Forum of Allergy & Rhinology. 2013;3(3):177-83.
  70. Koberlein J, Mosges R. Oralair(®):a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. Immunotherapy. 2013;5(1):13-21.
  71. Balaji R, Parasuramalu BG, Chandregowda BV, Gangaboraiah. Safety, tolerability, and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis. Allergologia et Immunopathologia. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23481554
  72. Liu LL, Guo DD, Liang QX, Ding S, Chen JY, Wu B, Li Q. Sublingual immunotherapy for experimental allergic conjunctivitis in a murine model induced by dermatophagoides farinae allergen. International Archives of Allergy and Immunology. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23548949
  73. Tourdot S, Airouche S, Berjont N, Moussu H, Betbeder D, Nony E, Bordas-Le Floch V, Baron-Bodo V, Mascarell L, Moingeon P. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. Vaccine. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23583462
  74. Cui L, Wang ZN, Xu ZQ, Xia ZF. Efficacy and safety of sublingual immunotherapy of allergic rhinitis in children between 4 and 5 years age group and 11 and 12 years age group. Zhonghua Er Bi Yan Hou Tou Jing wai Ke Za Zhi. 2013;48(1):17-21.
  75. Chiriac AM, Demoly P. Respiratory allergies. La Presse Medicale. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22884514
  76. Park IH, Hong SM, Lee HM. Efficacy and safety of sublingual immunotherapy in Asian children. International Journal of Pediatric Otorhinolaryngology. 2012;76(12):1761-6.
  77. Sieber J, Neis M, Brehler R, Folster-Holst R, Kapp A, Klimek L, Merk H. Increasing long-term safety of seasonal grass pollen sublingual immunotherapy: the ECRIT study. Expert Opinions on Drug Safety. 2012;11(1):7-13.
  78. Calderon  MA, Simons FE, Malling H, Lockey, RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302-11
  79. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. Journal of Allergy and Clinical Immunology. 2012;129(3):717-725.
  80. Scheinmann P, Pham Thi N, Karila C, de Blic J. Allergic march in children, from rhinitis to asthma; management, indication of immunotherapy. Archives of Pediatrics. 2012;19(3):330-4.
  81. Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, efficacy, and mode of action. Immunotherapy. 2012;4(2):201-12.
  82. Vichyanond P, Pensrichon R, Kurasirikul S. Progress in the management of childhood asthma. Asia Pac Allergy. 2012;2(1):15-25.
  83. Shaikh WA, Shaika SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy. 2012;67(6):741-3.
  84. Morris MS, Lowery A, Theodoropoulous DS, Duquette RD, Morris DL. Quality of life improvement with sublingual immunotherapy; a prospective study of efficacy. Journal of Allergy. 2012. Epub retrieved June 19, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22500181
  85. Trebuchon F, David M, Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy; a retrospective, observational study. International Journal of Immunopathology and Pharmacology. 2012;25(1):193-206.
  86. Woody J, Wise SK, Koepp S, Schlosser RJ. Clinical improvement after escalation for sublingual immunotherapy (SLIT). Ear, Nose and Throat Journal. 2011;90(9):16-22.
  87. Ciprandi G, Marseglia GL. Safety of sublingual immunotherapy. Journal of Biological Regulators and Homeostatic Agents. 2011;25(1):1-6.
  88. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clinical and Experimental Allergy 2011 Sep;41(9):1247-55.
  89. Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M, et al. Sublingual Immunotherapy in Polysensitized Patients: Effect on Quality of Life. Journal of Investigational Allergology and Clinical Immunology. 2010;20(4):274-279.
  90. Wise S, Woody J., Koepp S, Schlosser R. Quality of life outcomes with sublingual immunotherapy. American Journal of Otolaryngology. 2009;30:305-311.
  91. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2009;12 (1):167-173.
  92. Windom H., Lockey R. An update on the safety of specific immunotherapy. Current Opinion in Allergy and Clinical Immunology. 2008;8:571-576.
  93. Rodriguez-Perez N, Ambriz-Moreno MJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Annals of Allergy, Asthma, & Immunology. 2008;101:304-310.
  94. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy Online. December 2007, retrieved from http://ww.blackwell-synergy.com
  95. Moreno-Ancillo A, Moreno C, Ojeda P, Dominguez C, Barasona MJ, Garcia-Cubillana A, Martin, S. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. Journal of Investigational Allergology & Clinical Immunology. 2007;17:399-405.
  96. Dunsky E, et al. Anaphylaxis to sublingual immunotherapy. Allergy. 2006;61:1235-1244.
  97. Antico A, et al. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006;61:1236-1237.
  98. Larsen T, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy – a phase-1 study. Allergy. 2006;61:1173-1176.
  99. Frati F, et al. Dose dependence of efficacy but not of safety in sublingual immunotherapy. Monaldi Archives of Chest Disease. 2006;65(1):38-40.
  100. Kleine-Tebbe J, et al. Safety of a SQ-standarised grass allergen tablet for sublingual immunotherapy:A randomized, placebo-controlled trial. Allergy. 2006;61:181-184.
  101. Tripodi S, et al. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. International Archives of Allergy and Immunology. 2006;139:149-152.
  102. Di Rienzo V, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clinical and Experimental Allergy. 2005;35:560-564.
  103. Scolozzi R. Tolerability of the allergoid sublingual immunotherapy with a monomeric allergoid in patients with allergic rhinitis and/or asthma. Journal of Allergy and Clinical Immunology. 2004;113(2):(abs).
  104. Silvestris A. Tolerability of sublingual immunotherapy with monomeric allergoid in allergic sensitizations to house dust mite, Parietaria and grass. Journal of Allergy and Clinical Immunology. 2004;114(2):(abs).
  105. Grosclaude M, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. International Archives of Allergy and Immunology. 2003;129(3):248-253.
  106.  Hasan H, et al. Short report – evaluation of immunotherapy for seasonal and perennial allergic rhinitis using quality of life questionnaires. Current Allergy & Clinical Immunology. 2003; 16(1).
  107. Lombardi C, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy. 2001;56:989-992.
  108. Lombardi C, et al. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy. 2000;55:677-78.
  109. Andre C, et al. Safety of sublingual immunotherapy in children and adults. International Archives of Allergy and Immunology. 2000;121:229-234.
  110. Madonini E, et al. Safety and efficacy evaluation of sublingual allergen-specific immunotherapy – a retrospective, multicenter study. International Journal of Immunopathology and Pharmacology. 2000;13(2):77-81.
  111. Di Rienzo V, et al. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy. Vol. 54, pgs. 1110-1113, 1999.
  112. Ariano R, et al. Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double-blind study. Journal of Investigative Allergology and Clinical Immunology. 1998;8(3):155-160.
  113. Feliziani V, et al. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergologia et Immunopathologia. 1995;23(5):224-230.

6. Other Indications for Treatment (Foods and Chemicals)

  1. Vesna TS, Denisa D, Slavenka J, et al. Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. Iranian Journal of Allergy, Asthma and Immunology. 2016 Apr;15(2):112-21.
  2. Theodoropoulos DS, Stockdale CK, Duquette DR, Morris MS. Inhalant allergy compounding the chronic vaginitis syndrome: Characterization of sensitization patterns, comorbidities and responses to sublingual immunotherapy. Archives of Gynecology and Obstetrics. 2016 Apr 4. Epub ahead of print retrieved April 19, 2016 from https://www.ncbi.nlm.nih.gov/pubmed/27040422
  3. DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Veterinary Dermatology. 2016 Apr;27(2):82-e24. doi: 10.1111/vde.12284. Epub 2016 Jan 8.
  4. Dahl R, Roberts G, de Blic J, et al. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy and Asthma Proceedings. 2016 Mar;37(2):92-104. doi: 10.2500/aap.2016.37.3937. Epub 2016 Jan 21.
  5. Moingeon P, Cox L. Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America. Expert Review of Clinical Immunology. 2016 Feb 19:1-7. doi:10.1586/1744666X.2016.1147349. [Epub ahead of print]
  6. Nucera E, Aruanno A, Rizzi A, et al. Profilin desensitization: A case series. International Journal of Immunopathology and Pharmacology. 2015 Dec 18. pii: 0394632015621926. [Epub ahead of print]
  7. Sindher S, Fleischer DM, Spergel JM. Advances in the treatment of food allergy: Sublingual and epicutaneous immunotherapy. Immunology and Allergy Clinics of North America. 2016 Feb;36(1):39-54. doi: 10.1016/j.iac.2015.08.008.
  8. Barberi S, et al. Allergen immunotherapy and respiratory infections in children: an encouraging experience. Minerva Pediatrica. 2015 Nov 25. Epub ahead of print retrieved November 20, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/26605703
  9. Vazquez-Ortiz M, Turner PJ. Improving the safety of oral immunotherapy for food allergy. Pediatric Allergy and Immunology. 2015 Nov 23. doi: 10.1111/pai.12510. [Epub ahead of print]
  10. Ras L, de Groot H, Stengs CH, van Weissenbruch R. Persistence of treatment with 5-grass pollen tablets in patients with allergic rhinitis: a real-life study. Annals of Allergy, Asthma & Immunology. 2015 Nov 17. pii: S1081-1206(15)00703-6. doi: 10.1016/j.anai.2015.10.018. [Epub ahead of print]
  11. Melzer JM, Driskill BR, Clenney TL, Gessler EM. Sublingual immunotherapy for allergic fungal sinusitis. Annals of Otology, Rhinology & Laryngology. 2015 Oct;124(10):782-7. doi: 10.1177/0003489415583686. Epub 2015 Apr 22.
  12. Burk CM, Kulis M, Leung N, Kim EH, Burks AW, Vickery BP. Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy. Clinical & Experimental Allergy. 2015 Sep 12. doi: 10.1111/cea.12635. [Epub ahead of print]
  13. Chhiba KD, Singh AM, Bryce PJ. New developments in immunotherapies for food allergy. Immunotherapy. 2015 Aug 7;7(8):913-22. doi: 10.2217/IMT.15.55. Epub 2015 Aug 13.
  14. Ludman SW, Boyle RJ. Stinging insect allergy: current perspectives on venom immunotherapy. Journal of Asthma and Allergy. 2015 Jul 23;8:75-86. doi: 10.2147/JAA.S62288. eCollection 2015.
  15. Barberi S, et al. Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. Asia Pacific Allergy. 2015 Jul;5(3):163-9. doi: 10.5415/apallergy.2015.5.3.163. Epub 2015 Jul 29.
  16. Chiang D, Berin MC. An examination of clinical and immunologic outcomes in food allergen immunotherapy by route of administration. Current Allergy and Asthma Reports. 2015 Jun;15(6):35. doi: 10.1007/s11882-015-0536-y.
  17. Meglio P, et al. The oral food desensitization in the Italian allergy centres. European Annals of Allergy and Clinical Immunology. 2015 May;47(3):68-76. Epub ahead of print retrieved December 9, 2015 from http://www.ncbi.nlm.nih.gov/pubmed/25951144
  18. Fernandez-Rivas M. Fruit and vegetable allergy. Chemical Immunology and Allergy. 2015;101:162-70. doi: 10.1159/000375469. Epub 2015 May 21.
  19. Sato S, Yanagida N, Ebisawa M. Oral immunotherapy and potential treatment. Chemical Immunology and Allergy. 2015;101:106-13. doi: 10.1159/000371697. Epub 2015 May 21.
  20. Robison RG. Food allergy: Diagnosis, management, & emerging therapies. Indian Journal of Medical Research. 2014 Jun;139(6):805-13. Retrieved December 14 from http://www.ncbi.nlm.nih.gov/pubmed/25109714
  21. Kim EH, Burks W. Oral and sublingual immunotherapy. Current Treatment Options in Allergy. 2014 Mar 1;(1):48-57. doi: 10.1007/s40521-013-0004-7.
  22. Gorelik M1, et al. Suppression of the immunologic response to peanut during immunotherapy is often transient. Journal of Allergy and Clinical Immunology. 2015 May;135(5):1283-92. doi: 10.1016/j.jaci.2014.11.010. Epub 2014 Dec 24.
  23. Narisety SD1, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. Journal of Allergy and Clinical Immunology. 2015 May;135(5):1275-1282.e6. doi: 10.1016/j.jaci.2014.11.005. Epub 2014 Dec 18.
  24. Liu M1, Burks AW, Green TD. Tree nut allergy: risk factors for development, Mitigation of reaction risk and current efforts in desensitization. Expert Review of Clinical Immunology. 2015 May;11(5):673-9. doi: 10.1586/1744666X.2015.1032258. Epub 2015 Mar 31.
  25. Kulis M1, Wright BL2, Jones SM3, Burks AW4. Diagnosis, management, and investigational therapies for food allergies. Gastroenterology. 2015 May;148(6):1132-42. doi: 10.1053/j.gastro.2015.01.034. Epub 2015 Jan 26.
  26. Praticò AD1, Leonardi S. Immunotherapy for food allergies: a myth or a reality? Immunotherapy. 2015;7(2):147-61. doi: 10.2217/imt.14.115.
  27. Greenhawt MJ1, Vickery PB2. Allergist-reported trends in the practice of food allergen oral immunotherapy. Journal of Allergy and Clinical Immunology. In Practice. 2015 Jan-Feb;3(1):33-8. doi: 10.1016/j.jaip.2014.06.023. Epub 2014 Oct 29.
  28. Bublin M, Breiteneder H. Developing therapies for peanut allergy. International Archives of Allergy and Immunolog. 2014;165(3):179-94. doi: 10.1159/000369340. Epub 2014 Dec 20.
  29. Nowak-Wegrzyn A1, Albin S. Oral Immunotherapy for food allergy: mechanisms and role in management. Clinical & Experimental Allergy. 2014 Jul 31. doi:10.1111/cea.12382. [Epub ahead of print]
  30. Arkwright PD1, Stafford JC, Sharma V. Atopic dermatitis in children. Journal of Allergy and Clinical Immunology Practice. 2014 Jul-Aug;2(4):388-95. Doi:10.1016/j.jaip.2014.01.016.Epub 2014 Apr 18.
  31. Van Winkle RC1, Chang C. The biochemical basis and clinical evidence of food allergy due to lipid transfer proteins:a comprehensive review. Clinical Reviews in Allergy & Immunology. 2014 Jun;46(3):211-24. doi:10.1007/s12016-012-8338-7.
  32. Yang YH1, Chiang BL. Novel approaches to food allergy. Clinical Reviews in Allergy & Immunology. 2014 jun;46(3):250-7. doi:10.1007/s12016-013-8354-2.
  33. Berin MC. Future Therapies for IgE-Mediated Food Allergy. Current Pediatric Reports. 2014 Jun 1;2(2):119-126.
  34. Anagnostou K, Clark A. Peanut immunotherapy. Clinical and Translational Allergy. 2014, 4:30. doi :10.1186/2045-7022-4-30.
  35. Keet CA, Wood RA. Emerging therapies for food allergy. Journal of Clinical Investigation. 2014 May 1;124(5):1880-6. doi:10.1172/JCI72061. Epub 2014 May 1.
  36. Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Tavassoli M, Hoyte E, O’Riordan G, Blakemore A, Seki S, Hamilton RG, Nadeau KC. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Journal of Allergy and Asthma Clinical Immunology. 2014 Feb 20;10(1):7.
  37. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. Journal of Allergy and Clinical Immunology. 2014 Feb;133(2):468-75. Epub 2013 Dec 19
  38. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. Journal of Allergy and Clinical Immunology. 2014 Feb;122(2)318-23.
  39. Greenhawt MJ. Oral and sublingual peanut immunotherapy is not ready for general use. Allergy and Asthma Proceedings. 2013 May-Jun;34(3):197-204.
  40. Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, Scurlock AM, Jones SM, Burks AW. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. Journal of Allergy and Clinical Immunology. 2013 Aug;132(2):476-47
  41. Wang J, Sampson HA. Oral and sublingual immunotherapy for food allergy. Asian Pacific Journal of Allergy and Immunology. 2013 Sep;31(3):198-209.
  42. Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. Journal of Allergy and Clinical Immunology. 2013 Sep;132(3):737-739. Epub 2013 Jun 25.
  43. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. Journal of Allergy and Clinical Immunology. 2013 Dec;132(6):1368-74.
  44.  Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. Current Opinion in Immunology. 2013 Dec;25(6):781-787.
  45. Nurmatov U, Devereux G, Worth A, Healy L, Sheikh A. Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis. British Journal of Nutrition. 2014 Jan 14;111(1):12-22.
  46. Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: Oral, sublingual and epicutaneous. Journal of Allergy and Clinical Immunology: In Practice. 2014 Feb;133(2):318-323.
  47. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablin D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson HA, Consortium of Food Allergy Research. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Immunology. 2013;131(1):119-27.
  48. Yang YH, Chiang BL. Novel approaches to food allergy. Clinical Reviews in Allergy & Immunology. 2013. Epub ahead of print retrieved May 15, 2013 from http://www.ncbi.nlm.nih.gov/pubmed/23329212
  49. Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, Scurlock AM, Jones SM, Burks AW. Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison. Journal of Allergy and Clinical Immunology. 2013. Epub ahead of print retrieved May 15, 2013, from http://www.ncbi.nlm.nih.gov/pubmed/23534975
  50. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, Oude Elberink JN. Venom immunotherapy for preventing allergic reactions for insect stings. Cochrane Database of Sysematic Reviews. 2012;10.
  51. Van Winkle RC, Chang C. The biochemical basis and clinical evidence of food allergy due to lipid transfer proteins: A comprehensive review. Clinical Reviews in Allergy and Immunology. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/23179517
  52. Virkud YV, Vickery BP. Advances in immunotherapy for food allergy. Discover Medical. 2012;14(76):159-65.
  53. Narisety SD, Keet CA. Sublingual vs. oral immunotherapy for food allergy: Identifying the right approach. Drugs. 2012;72(15):1977-89.
  54. Sanchez-García S, Rodríguez Del Río P, Escudero C, Martínez-Gómez MJ, Ibañez MD. Possible eosinophilic esophagitis induced by milk oral immunotherapy. Journal of Allergy and Clinical Immunology. 2012 Apr;129(4):1155-7.
  55. Nettis E, Delle Donne P, Di Leo E, Fantini P, Passalacqua G, Bernardini R, Canonica GW, Ferrannini A, Vacca A. Latex immunotherapy: state of the art. Annals in Allergy, Asthma, and Immunology. 2012;109(3):160-5.
  56. McWilliams L, Moussallem T, Burks W. Future therapies for food allergy. Human Vaccines and Immunotherapeutics. 2012. Epub ahead of print retrieved December 3, 2012, from http://www.ncbi.nlm.nih.gov/pubmed/22894951
  57. Mousallem T, Burks AW. Immunology in the Clinic Review Series; focus on allergies: immunotherapy for food allergy. Clinical Experimental Immunology. 2012; 167(1):26-31.
  58. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis and hypersensitivity reactions to foods, drugs, and insects in 2011. Journal of Allergy and Clinical Immunology. 2012;129(1):76-85.
  59. Beyer K. A European perspective on immunotherapy for food allergies. Journal of Allergy and Clinical Immunology. 2012;129(5):1179-84.
  60. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. Journal of Allergy and Clinical Immunology. 2012;129(2):448-55.
  61. Burks AW1, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy in children. New England Journal of Medicine. 2012 Jul 19;367(3):233-43.
  62. Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, Staats H, Burks AW. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. Journal of Allergy and Clinical Immunology. 2012;129(4):1159-62.
  63. Kari, O., Saari, KM. Treatment of eye allergies. Duodecim. 2012;128(3):291-7.
  64. Lasa Luaces EM, Tabar Purroy AI, Gargia Figueroa BE, Anda Apinaniz M, Sanz Laruga ML, Raulf-Heimsoth M, Barber Hernandez D. Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children. Annals of Allergy, Asthma, and Immunology. 2012;108(5):367-72.
  65. Crisafulli G, Caminiti L, Pajno GB. Oral desensitization for immunoglobulin E-mediated milk and egg allergies. Israel Medical Association Journal. 2012;14(1):53-6.
  66. Otsu K, Fleischer DM. Therapeutics in food allergy: The current state of the art. Current Allergy and Asthma Reports. 2012;12(1):48-54.
  67. Cortellini G, Spadolini I, Santucci A, Cova V, Conti C, Corvetta A, Passalacqua G. Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: A case report. European Annals of Allergy and Clinical Immunology. 2011;43(5):162-4.
  68. Vickery BP, Scurlock AM, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Perry TT, Jones SM, et al. Early and persistent gastrointestinal side effects predict withdrawal from Peanut oral immunotherapy (OIT). Journal of Allergy and Clinical Immunology. February 2011;127(2)AB26.
  69. Mauro M, Russello M, Invorvaia C, Gazzola G, Frati F, Moingeon P, et al. Birch-Apple syndrome treated with birch pollen immunotherapy. International Archives of Allergy and Immunology. 2011;156(4):416-422.
  70. Varshney P1, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. Journal of Allergy and Clinical Immunology. 2011 Mar;127(3):654-60.
  71. Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. Journal of Allergy and Clinical Immunology. 2011 Mar;127(3):640-6.
  72. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: other indications. Immunology and Allergy Clinics of North America. 2011;31(2):279-87.
  73. Kulis M, Vickery BP, Burks AW. Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunological Research. 2011;49(1-3):216-26.
  74. Garcia BE, Gonzalez-Mancebo E, Barber D, Martin S, Tabar AI, Diaz de Durana AM,et al. Sublingual immunotherapy in peach allergy: monitoring molecular sensitizations and reactivity to apple fruit and Platanus pollen. Journal of Investigational Allergology and Clinical Immunology. 2010;20(6):514-20.
  75. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. Journal of Allergy and Clinical Immunology. 2010 Jun;125(6):1322-6. Epub 2010 May 11
  76. Buyukozturk S, Gelincik A, Ozseker F, Colakoglu B, Dal M. Latex Sublingual Immunotherapy: Can its safety be predicted? Annals of Allergy, Asthma & Immunology. 2010 April;104(4):330-42.
  77. Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, Perry TT, Jones SM, Burks AW. Adverse reactions during peanut oral immunotherapy home dosing. Journal of Allergy and Clinical Immunology. 2009 Dec;124(6):1351-2.
  78. Pereira C, Bartolome B, Asturian J, Ibarrola I, Tavares B, Loureiro G, et.al. Specific sublingual immunotherapy with peach LTP (Pru p 3). One year treatment: a case report. Cases Journal. 2009;2:6553.
  79. Patriarca G, Nucera E, Roncallo C, Aruanno A, Lombardo C, Decinti M, et.al. Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy. Journal of Allergy and Clincal Immunology. 2009 Aug;124(2);385.
  80. Skripak J, Wood R. Mammalian milk allergy: avoidance strategies and oral desensitization. Current opinion in Allergy and Clinical Immunology. 2009;9:259-264.
  81. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009 Dec;124(6)1549-55.
  82. Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Díaz de Durana MD, García BE, Gonzalez-Mancebo E, Martín S, Barber D, Rico P, Tabar A. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009 Jun; 64(6):876-83.
  83. Atkins D. Food allergy:diagnosis and management. Primary Care. 2008 Mar;35(1):119-40.
  84. Beyer K, Wahn U. Oral immunotherapy for food allergy in children. Current Opinion in Allergy and Clinical Immunology. 2008;8:553-556.
  85. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, Matsui EC, Burks AW, Wood RA. A randomized, double blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. Journal of Allergy and Clinical Immunology. 2008 Dec;122(6):1154-60. Epub 2008 Oct 25.
  86. Nucera E, Schiavino D, Buomomo A, Pollastrini E, Altomonte G, Pecora V. et al. Sublingual-Oral Rush Desensitization to Mixed Cow and Sheep Milk: A Case Report. Journal of Investigational Allergology and Clinical Immunology. 2008;18(3):219-222.
  87. Burks W, Laubach S, Jones S. Oral tolerance, food allergy, and immunotherapy: Implications for future treatment (Update Review). Journal of Allergy and Clinical Immunology. 2008 June;121(6):1344-50.
  88. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchi D, Spadolini I, Canonica WG, Passalacqua, G.. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2008 Jul;122(1):44-8.
  89. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. Journal of Allergy and Clinical Immunology. January 2008, retrieved February 1, 2008 from www.jacionline.org.
  90. Skripak JM, Matsui EC, Mudd K, et al. The natural history of IgE-mediated cow’s milk allergy. Journal of Allergy and Clinical Immunology. 2007;120 (5):1172–7
  91. Munoz-Lopez F. Food allergy: oral tolerance or immunotherapy. Allergologia et Immunopathologia. 2007;35(5):165-168.
  92. Nettis E, Colanardi MC, Soccio AL, Marcandrea M, Pinto L, Ferrannini A, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. British Journal of Dermatology. 2007; 156:674-681.
  93. Pajno G, Caminiti L, Vita D, Barberio G, Salzanno G, Lombardo F. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology. 2007;120:164-170.
  94. Patriarca G. et al. Oral specific desensitization in food-allergic children. Digestive Diseases Sciences. 2007;52(7):1662-72.
  95. Passalacqua G, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A Novel SLIT formulation during a Year). Pediatric Allergy and Immunology. 2007;18:58-62.
  96. Buchanan A. et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. Journal of Allergy and Clinical Immunology. 2007;119(1):199-205.
  97. Kinaciyan T, et al. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. Journal of Allergy and Clinical Immunology, 2007 April;119(4):937-43.
  98. Patriarca G, et al. Oral Rush Desensitization in Peanut Allergy: A Case Report. Digestive Diseases and Sciences. 2006;51(3):471-473.
  99. Sun J-B, et al. Sublingual Tolerance Induction with Antigen Conjugated to Cholera Toxin B Subunit Induces Fox p3+CD25+CD4+ Regulatory T Cells and Suppresses Delayed-Type Hypersensitivity Reactions. Scandinavian Journal of Immunology. 2006;64:251-259.
  100. de Boissieu D, Dupont C. Sublingual immunotherapy for cow’s milk protein allergy: a preliminary report. Allergy. 2006;61:1238-1239.
  101. Kerzl R, et al. Life-threatening anaphylaxis to kiwi fruit: Protective sublingual allergen immunotherapy effect persists even after discontinuation. Journal of Allergy and Clinical Immunology; 2007 Feb;119(2)507-8.
  102. Scurlock A, Lee L, Burks AW. Food Allergy in Children. Immunology and Allergy Clinics of North America. 2005 May;25(2):369-388.
  103. Enrique E. et al. Sublingual immunotherapy for hazelnut food allergy: A randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. Journal of Allergy and Clinical Immunology.2005;Vol. 116(5):1073-1079.
  104. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy. 2004 Sep;59(9):980-7.
  105. Cistero Bahima A, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. Journal of Investigational Allergology and Clinical Immunology. 2004;14(1):17-25.
  106. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. Journal of Allergy and Clinical Immunology; 2003 June;111(6):1406-09.
  107. Patriarca G. et al. Oral desensitizing treatment in food allergy: clinical and immunologic results. Alimentary Pharmacology Therapy. 2003 May;17(9):459-465.
  108. Patriarca G. Sublingual Desensitization: A New Approach to Latex Allergy Problem. Anesthesia & Analgesia. 2002;95:956-960.
  109. Sicherer SH. Clinical implications of cross-reactive food allergens. Journal of Allergy and Clinical Immunology. 2001 Dec;108(6):881-90.
  110. Skolnick HS, Conover-Walker MK, Koerner CB, et al. The natural history of peanut allergy. Journal of Allergy and Clinical Immunology. 2001;107 (2):367–74.
  111. Nucera E. Immunological Aspects of Oral Desensitization in Food Allergy. Digestive Diseases and Sciences. 2000;45(3):637-641.
  112. Sampson HA. Food allergy. Part1: Immunopathogenesis and clinical disorders. Journal of Allergy and Clinical Immunology. March 1999 March;103(5):717-28.
  113. Patriarca G, et al. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology. 1998;45(19):52-58.
  114. Morris DL. Intradermal Testing and Sublingual Desensitization for Nickel. Cutis. 1998;61(3):129-132.
  115. Patriarca G, et al. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology. 1998;45(19):52-58.
  116. Panzani RC, et al. Oral hyposensitization to nickel allergy: preliminary clinical results. International Archives of Allergy and Immunology. 1995;107(1-3):251-254.
  117. Morris D. Use of sublingual antigen in diagnosis and treatment of food allergy. Annals of Allergy, Asthma & Immunology. 1969;27(6):289-94.

7. Allergic Trends and Supporting Data

  1. Branum AM1, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009 Dec;124(6):1549-55. doi: 10.1542/peds.2009-1210. Epub 2009 Nov 16.
  2. Gupta RS1, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, Holl JL. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011 Jul;128(1):e9-17. doi: 10.1542/peds.2011-0204. Epub 2011 Jun 20.